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PREFACE 
The literature review includes an update on bovine mastitis, with special reference to 
infections caused by Staphylococcus aureus. Lactic acid bacteria (LAB), the bacteriocins 
they produce and their application in mastitis control are also discussed. 
 
The paper, “Prevention and treatment of Staphylococcus aureus mastitis in dairy cows by 
using the cyclic peptide AS-48”, has been written according to the style of J. Dairy 
Research. 
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SUMMARY 
 
The effect of the bacteriocin-like peptide AS-48, produced by Enterococcus faecalis 
FAIRE 92, was tested against a mastitis isolate of Staphylococcus aureus in an in vivo 
and in vitro study. During initial tests peptide AS-48 showed no significant activity 
towards S. aureus, even with a ten-fold concentrated cell-free supernatant. Activity was 
obtained only after purification with Triton X-114 phase partitioning, followed by cation 
exchange chromatography. Titers for the purified peptide varied between 3200 and 12800 
AU/ml. The purified peptide also exhibited activity towards Streptococcus agalactiae and 
Streptococcus dysgalactiae, but not against Escherichia coli. 
 
The size of peptide AS-48 was determined at 7150 Da, based on electronspray mass 
spectrometry and SDS-PAGE. Complete inhibition of cell growth was obtained by 
adding 1ml of the purified peptide (3200 AU/ml) to 100 ml of cells of S. aureus in the lag 
growth phase. When the same concentration of peptide AS-48 was added to a culture of 
S. aureus in mid-exponential growth, a slight decrease in viable cell numbers was 
recorded, which lasted for only 30 min. Cell growth commenced thereafter. 
 
In situ experiments in cows were done with purified peptide AS-48, encapsulated in 
liposomes. These in vivo studies were conducted by administering peptide AS-48 (6400 
AU/ml) to different udder quarters. In a prevention trial, i.e. where quarters were pre-
treated with peptide AS-48, a reduction close to 90% in the viable cell numbers of S. 
aureus was recorded relative to the control quarters, which were not treated with the 
peptide. A 50% reduction in somatic cell count (SCC) was recorded. In the treatment 
trial, i.e. infected quarters treated with peptide AS-48, a reduction of up to 94% in viable 
cell numbers of S. aureus was recorded. In the same quarters, a reduction in SCC 
amounted to almost 80%. 
 
A recombinant strain was constructed by conjugating plasmid 92 (p92), encoding peptide 
AS-48, from Enterococcus faecalis FAIRE 92 to E. faecalis FA2/Ent, which produces 
enterocins 1071A and 1071B. Southern blot hybridization experiments revealed the 
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presence of plasmid p92 in the recipient strain without the loss of plasmid pEF1071, 
which encodes enterocins 1071A and 1071B. All three antimicrobial peptides, i.e. 
enterocin 1071A, enterocin 1071B and peptide AS-48, were produced in transconjugant 
FA2/Ent/AS-48. The spectrum of antimicrobial activity of the transconjugant was greater 
than that recorded for strains FA2/Ent and FAIRE 92, respectively and included E. 
faecalis, Bacillus cereus, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus 
curvatus, Lactobacillus fermentum, Lactobacillus plantarum, Lactobacillus reuteri, 
Lactobacillus sakei, Leuconostoc cremoris, Leuconostoc pentosaceus, Staphylococcus 
carnosus and S. aureus. These organisms are not inhibited by strain FA2/Ent. However, 
low levels of peptide AS-48 was produced by strain FA2/Ent/AS-48. Further research in 
fermentation and gene expression will be needed before the transconjugant E. faecalis 
FA2/Ent/AS-48 may be used in the treatment of mastitis. 
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OPSOMMING 
 
Die effek van die bakteriosien-agtige, peptied AS-48, geproduseer deur Enterococcus 
faecalis FAIRE 92, is gedurende ‘n in vivo en in vitro studie teen ‘n mastitiese 
Staphylococcus aureus-isolaat getoets. Aanvanklike toetse met peptied AS-48, selfs 
tienvoudig gekonsentreerde selvrye supernatant, het geen beduidende aktiwiteit teen S. 
aureus getoon nie. Aktiwiteit is eers verkry na suiwering met Triton X-114 fase-skeiding 
gevolg deur katioon uitruilingschromatografie. Titers vir die gesuiwerde peptied het 
tussen 3200 en 12800 AE/ml gewissel. Die gesuiwerde peptied het ook aktiwiteit teen 
Streptococcus agalactiae en Streptococcus dysgalctiae getoon, maar nie teen Escherichia 
coli nie. 
 
Peptied AS-48 het ‘n molekulêre massa van 7150 Da, soos bepaal met elektronsproei- 
massa spektrometrie en SDS-PAGE. Totale inhibisie van selgroei is verkry deur 1 ml 
gesuiwerde peptied AS-48 (3200 AE/ml) by ‘n 100 ml kultuur van S. aureus in die 
sloerfase te voeg. Dieselfe konsentrasie peptied AS-48, toegevoeg tydens die mid-
eksponensiële groeifase, het egter slegs ‘n klein vermindering in die aantal lewende selle 
teweeg gebring en het ook vir slegs ‘n 30 min geduur. Selgroei het hierna weer normaal 
voort gegaan.  
 
In situ eksperimente op koeie is uitgevoer met gesuiwerde peptied AS-48, ge-
enkapsuleerd in liposome. Hierdie In vivo studies is onderneem deur peptied AS-48 
(6400 AE/ml) in verskillende kwarte van die uier, kunsmatig of reeds geïnfekteerd met S. 
aureus, toe te dien. In ‘n voorkomings-eksperiment waar kwarte vooraf met peptied AS-
48 behandel is, is ‘n verlaging van byna 90% in die lewende seltelling van S. aureus 
relatief tot die kontrole kwarte, sonder behandeling met peptied AS-48, verkry. ‘n 50% 
verlaging in die somatiese seltelling (SST) is verkry. In die behandelings-eksperiment, 
waar geïnfekteerde kwarte met peptied AS-48 behandel is, is ‘n verlaging van byna 90% 
in lewende S. aureus selle gevind. In dieselfde kwarte is ‘n verlaging van byna 80% in 
die SST genoteer. 
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‘n Rekombinante ras is gekonstrueer deur plasmied 92 (p92), wat kodeer vir peptied AS-
48, vanaf Enterococcus faecalis FAIRE 92 na E. faecalis FA2/Ent, wat enterosien 1071A 
en 1071B produseer, te konjugeer. Southern-klad hibridisasie het die teenwoordigheid 
van plasmied p92 in die ontvanger ras, sonder die verlies van plasmied pEF1071 wat 
enterosien 1071A en 1071B kodeer, getoon. Al drie antimikrobiese peptiede, nl. 
enterosien 1071A, enterosien 1071B en peptied AS-48, is deur die transkonjugant 
FA2/Ent/AS-48 geproduseer. Die spektum van antimikrobiese aktiwiteit van die 
transkonjugant vand die transkonjugant is breër as dié van rasse FA2/Ent en FAIRE 92, 
onderskeidelik en het ook E. faecalis, Bacillus cereus, Lactobacillus acidophilus, 
Lactobacillus casei, Lactobacillus curvatus, Lactobacillus fermentum, Lactobacillus 
plantarum, Lactobacillus reuteri, Lactobacillus sakei, Leuconostoc cremoris, 
Leuconostoc pentosaceus, Staphylococcus carnosus en S. aureus ingesluit. Hierdie 
organismes word nie deur ras FA2/Ent geïnhibeer nie. Lae vlakke van peptied AS-48 is 
egter deur ras FA2/Ent/AS-48 geproduseer. Verdere navorsing in fermentasie en geen-
uitdrukking is nodig voordat E. faecalis FA2/Ent/AS-48 in die behandeling van mastitis 
gebruik kan word. 
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INTRODUCTION 
 
Mastitis, also known as intramammary infection (IMI), occurs in all mammalian species, 
but is particularly important in dairy cattle (7, 21). Mastitis is caused by both non-
infectious (traumatic or toxic) and infectious agents. However, bacterial infections are the 
main cause of the disease in cattle. The bacteria usually gain entry to the udder through 
the teat (streak) canal, leading to swelling, fever, redness, pain and abnormal lactation 
(7). 
 
Bovine mastitis is from an economic viewpoint the most costly disease confronting the 
dairy industry (8, 14, 17, 21, 36). Approximately 17-20% of dairy cattle world-wide 
suffer from mastitis and at least 50% of cows suffer at least one outbreak of clinical 
mastitis per lactation (3, 36). Major losses are experienced as a result of reduced milk 
production (70%), milk discarded during and after therapy (8%), drugs and veterinary 
expenses (8%) and death or premature culling (14%) (7, 8, 13, 14, 17, 36). In certain 
cases one or more quarters of the udder of the infected animals may become permanently 
damaged. In the United States, financial losses due to mastitis is estimated at 200 dollars 
per animal per year, with an overall loss of 2 billion dollars per year (1, 8, 14, 36). The 
estimated costs involved in the treating of mastitis in South Africa was close to R190 
million in 1978, which increased to R380 million in 1994. This figure is estimated to 
increase to R 480 million in 2003 (12). 
 
Streptococcus agalactiae has been the most common cause of mastitis prior to 1940. 
However, with the increased use of antibiotics, the prevalence of S. agalactiae decreased, 
whilst outbreaks of Staphylococcus aureus, coliform bacteria, Mycoplasma spp., 
Streptococcus uberis and Staphylococcus epidermidis increased (7, 21). In the Western 
Cape, Escherichia coli, Streptococcus dysgalactiae, S. agalactiae and S. aureus are the 
main causative organisms of mastitis. Control of the disease involves hygienic practices 
and infusion of antibiotic drugs into the udder. On average 33 million antibiotic 
treatments are given each year in the United States (3, 21). 
 
Through the use of lactic acid bacteria (LAB) and specifically small peptides, viz. 
bacteriocins, a low cost-effective method of controlling and treating mastitis may be 
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achieved. This should also lead to a direct increase in milk yield. LAB enjoys GRAS 
(generally regarded as safe) status. Most of the antimicrobial peptides (bacteriocins) they 
produce are also classified as GRAS.  
 
In this study we determined, in vitro and in vivo, the inhibitory activity of the cyclic 
peptide AS-48, produced by Enterococcus faecalis FAIRE 92 and classified as a 
bacteriocin, against a strain of S. aureus isolated from mastitic milk. In the in vivo 
studies, peptide AS-48 was liposome encapsulated and administered directly into the teats 
of cows. 
 
Plasmid p92, encoding peptide AS-48 in E. faecalis FAIRE 92, was conjugated to E. faecalis FA2/Ent 
which contains the plasmid encoding enterocins 1071A and 1071B. The rationale behind this was to 
develop a strain (FA2/Ent/92) with a broader spectrum of antimicrobial activity than E. faecalis FA2/Ent. 
Further research will be conducted to determine if the transconjugant can be used in the prevention of 
mastitis in dairy cows. 
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THE BOVINE UDDER 
 
Anatomy of the bovine udder 
 
The udder (Fig.1) is a skin gland and weighs in a full-grown cow between 10-25 kg. It 
consists of four individual milk glands, also known as quarters. Each quarter functions 
independently, with no mixing of milk between quarters. The size and shape of each teat 
that drains a quarter is independent of the size and shape of the udder (28). 
 
The teat canal is situated at the lower end of the teat. It is approximately 0.5-1.0 cm in 
length and is closed by the teat sphincter muscle. This muscle, Fürstenberg’s rosette, 
prevents contaminants entering the udder and loss of milk inbetween milkings. The teat 
cistern is at the top of the teat canal and Fürstenberg’s rosette, while the gland cistern is 
found at the top of the teat cistern and situated in the udder. Since there is no definitive 
separation, the teat and gland cistern are continuous. Five to twenty lactiferous (milk) 
ducts branch out of the gland cistern that in turn branches out into very fine lactiferous 
tubules which eventually end in an alveolus. The alveolus consists of a single layer of 
milk producing cells on the inside of a base membrane. This layer of epithelial cells 
surrounds the lumen or cavity inside the alveolus into which the milk is secreted (28). 
 
Resistance mechanisms of the bovine udder 
 
For mastitis to develop, bacteria must be able to penetrate the teat canal, progress to the 
milk-producing tissues, and induce inflammation. The tissues of the teat have a marked 
influence on the ability of udder pathogens to establish an infection. Mammary defenses 
ensure that most infections persist as chronic rather than acute mastitis. The teat canal 
and associated tissue (Fig.1) provide the first barrier to mammary pathogens and thus 
have an important role in mastitis control (25). 
  
There are three primary defense mechanisms provided by the teat canal. This includes 
adsorption of bacteria to keratin, removal of bacteria-coated keratin during machine 
milking (19), and drying out of the canal lumen which allows the resealing of keratanized 
surfaces (25). Bacteria adsorb strongly to keratin and up to a million organisms can be 
 8
removed by the teat canal at any given time. The sphincter muscle functions by 
maintaining a tight closure of the canal, thereby limiting bacteria to enter at the teat 
orifice (opening). Loss of muscle tone may increase susceptibility to IMI, i.e. more 
infections occur in quarters with leaky teat canals (24, 25). Studies have shown that teat 
canals of quarters that are large in diameter and with a thinner keratinous canal lining are 
more susceptible to infections (6). 
 
 
Fig.1. Schematic diagram of the bovine udder 
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The second barrier of the bovine udder is formed by the somatic cells in milk (22). 
Somatic cells consist of many types such as neutrophils, macrophages, lymphocytes, 
eosinophils, and various epithelial cell types of the mammary gland (14, 15). Milk 
producing cells also wear off and die during the milk production process and through 
normal aging. It is then secreted in the milk contributing to the milk somatic count (29). 
 
When the mammary gland is infected, the number and predominant types of somatic cells 
undergo a rapid transition. The relative proportion of cell types shifts to neutrophils, 
being more than 95% (14, 15, 18, 24). This transition, resulting in a higher somatic cell 
count (SCC) and showing clots or flakes, takes only a few hours and is part of the normal 
host defense mechanism (15, 18). The function of neutrophils in milk is to engulf and 
digest the invading bacteria. When the bacteria are destroyed, the recruitment of 
neutrophils into the gland ceases. Only a mild inflammatory episode is required to restore 
health in the gland (14, 15, 24). 
 
Sometimes the innate defense mechanism of the mammary gland loses the battle with the 
bacteria. The bacteria multiply and release large quantities of toxins. Various and larger 
quantities of soluble factors are then released by many of the various cell types in the 
mammary gland. This elicits a massive recruitment of additional leukocytes, mostly 
neutrophils, into the gland (14, 15, 16). 
 
 
BOVINE STAPHYLOCOCCAL MASTITIS 
 
Epidemiology of S. aureus 
 
Mastitis is caused by a variety of bacteria, including aerobic, facultatively anaerobic, 
micro-aerophilic and anaerobic genera, and mycoplasmas, yeasts, fungi, moulds, algae, 
viruses, and rickettsias. Micro-organisms other than streptococci and staphylococci play a 
minor role (7, 14). 
 
The genus Staphylococcus consists of more than 23 species (38). In cattle S. aureus 
survives in different environments, such as the skin, bedding, milk and milk secreting 
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tissue (4, 38). The species is, however, not commonly found on healthy teat skin, but 
readily colonize or grow in the teat canal. This is especially the case with lesions or sores 
in the teat orifice (7, 14, 37). The other major source of infection is infected milk (38). S. 
aureus may, however, persist for long periods of time in other parts of the body, such as 
the nose, vagina, and infected tonsils. Spreading of the organism occurs during milking 
(7). 
 
Other organisms include Streptococcus spp. and coliform bacteria. They also occur on the 
surface of materials and objects, including bedding, milking machines, and milker’s 
hands that have been contaminated with milk (36). 
 
Pathogenesis of S. aureus 
 
Some strains of S. aureus are tissue invaders and are extremely damaging to the udder 
parenchyma due to the release of toxins. The adherence of S. aureus to fibronectin is an 
important step of localization. Initially, the bacteria damage the epithelium lining of the 
teat and udder cisterns. They then move to the parenchyma, where deep-seated foci of 
infection are established. This is followed by abscessation, with fibrous encapsulation 
being a mechanism for restricting infection to localized areas (7). 
 
During the course of staphylococcal mastitis, the extent and distribution of tissue damage 
is highly variable; sometimes only small areas of the gland are involved. In such areas, 
necrotic epithelial cells lining alveoli or ducts are cast off and obstruct the duct system, 
causing involution of remaining functional alveoli and formation of scar tissue. 
Obstructed ducts may reopen and release staphylococci, which then infect other areas of 
the gland. This process may be repeated, causing cycles of infection and reinfection in 
different sites in the quarter. When microorganisms remain within the obstructed ducts 
and damaged tissue, abscesses may develop, leading to lumps (7). 
 
Pathology of S. aureus 
 
Staphylococcal mastitis may be peracute, acute, subacute or chronic, the latter being the 
most common. Peracute to acute gangrenous mastitis, which may be restricted to the teat 
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or a specific quarter, is characterized by dark red to black and dull tissue. Necrosis and 
venous thrombosis, which are the main features of the lesion, may extend throughout the 
gland or be restricted to foci within it. If the infected animal remains alive for some time, 
the gangrenous tissue is excreted through the teats within a week, leaving a raw, purulent 
surface (7). 
 
In less severe forms of staphylococcal mastitis, the onset is subtle and results in the 
development of pyogranulomas. Bacteria are present within the lesions and throughout 
the affected tissue. As the lesions progress, a marked granulomatous mastitis with 
fibroplasia develops. This process is referred to as botryomycosis (7). 
 
 
SOMATIC CELL COUNT (SCC) 
 
The SCC in milk is an indication of the level of infection in the udder (27). Various 
factors affect the SCC, as discussed below. 
 
1. Infection status 
This is the single most important factor affecting SCC in milk. Major pathogens such as 
S. aureus, S. agalactiae and coliform bacteria cause higher average SCC than minor 
pathogens such as Corynebacterium bovis and the coagulase-negative staphylococci (14, 
26). 
 
2. Age 
Apart from the infection status, lactation number, i.e. age, has the greatest effect on SCC. 
Older cows have a higher SCC, probably because they have been exposed to a greater 
variety of microorganisms. Furthermore, infections in older animals lasts longer and 
generally causes more extensive tissue damage (14, 26). 
 
3 Stage of lactation 
The SCC in milk of non-infected cows is high at calving and at drying off, with lower 
counts from peak to midlactation (14, 26). 
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4. Season 
The highest SCC generally occurs during summer with the lowest counts in winter. The 
cell counts of summer milk herds are usually 43% higher than winter milk herds (16). 
The high SCC is most probably caused by higher humidity and less sound management 
practices. Variation in SCC should, however, not be linked to weather conditions only 
(14, 26). 
 
5. Stress 
Cows harboring subclinical mammary infections respond to stress like isolation, weather 
change, agitation, thermal stress and gathering before milking with significant increases 
in milk SCC. Uninfected cattle, however, do not appear to respond in any significant 
proportion (14, 26). 
 
6. Diurnal variations 
Significant fluctuations in milk SCC occur depending on the time of sampling. Somatic 
cell counts are the highest 1 to 3 hours after milking, followed by a steady decline until 
the next sampling. Milk sampled in the afternoon usually has twice the number of SCC 
compared to milk sampled in the morning. SCC in quarter milk samples may vary as 
much as five-fold in uninfected cows, depending on when samples were collected (14, 
26). 
 
7. Day-to-day variation 
Daily variation in individual cows is considerably more in infected than in uninfected 
animals. Herds with a high mastitis incidence also have greater variation in either daily or 
monthly SCC (26). 
 
8. Somatic Cell Count Testing Methodology 
Sample collection, storage, transport, and test procedures all influence SCC results. 
Recently, considerable effort has been made to standardize SCC test procedure and 
calibration of cell counting instruments (26). 
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9. Management 
Consistent use of a teat dip, dry cow therapy, individual towels to wash and dry teats, 
milking order, type of housing, bedding and stall maintenance, milking system design 
and maintenance, and manure handling have a great impact on herd SCC (26). 
 
10. Breed difference 
Recently there have been reports on breed differences in SCC (26). The variability in 
SCC within a breed is greater than differences in SCC among breeds (14). However, 
further research is needed to substantiate these findings. 
 
 
FACTORS AFFECTING THE INCIDENCE OF MASTITIS 
 
Various factors affect the incidence of mastitis in a dairy herd. Main factors are the 
environment (housing, bedding, etc.), the animal and the milking machine. 
 
1. Housing 
When cows are housed, adequate space is important in minimizing infection of the udder 
(16). Overcrowding induces problems of sanitation, availability of nutrients and feeding 
space, and the possibility of stress in some cows. Crowding has also been reported to 
increase the SCC in milk. Adequate housing implies light, airy buildings free from drafts, 
stalls of adequate size, plenty of bedding, daily removal of manure, and exercise yards or 
drylots maintained free of wire, stones, or sharp objects (5). 
 
2. Milking machine 
The milking machine affects the incidence of mastitis by injuring the mammary tissue by 
overmilking. The rate of infection is also increased when quarters are left unmilked for a 
period of time.  Incomplete milking aggravates existing mastitis infections. The milking 
machine may also transfer infections from one cow to another. Other factors influencing 
mastitis are pressure changes in the teat cup, slipping of liners and airflow (7, 16). 
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3. Cow 
Individual animals vary greatly in their resistance to mastitis, a phenomenon which may 
be linked with udder conformation. Large pendulous udders are more susceptible to 
infections due to more frequent injuries. The size and shape of a teat are not significantly 
related to infection rate, but the width of the teat sphincter is closely associated with both 
milking rate and susceptibility to udder infections. Excessive hard milkers and cows 
which run milk freely are the most likely candidates to become infected, but milkabality 
and resistance to mastitis are not incompatible. Cows can inherit resistance to this disease 
(5, 16). 
 
4. Other conditions that affect the incidence of mastitis 
i) Milk yield 
The possibility of a positive connection between high milk yields and the incidence of 
mastitis is dubious. In certain instances there is no significant association between the 
level of milk production and the incidence of mastitis, while in others there is a positive 
connection between a high level of milk production and the incidence of infection. 
Although there are doubts whether there is a connection between milk yield and mastitis, 
it is a sound policy to pay particular attention to the health of the udders of high yielding 
cows (16). 
 
ii) Stage of lactation 
Increases in the incidence of clinical mastitis in cows have been reported to occur during 
31 days post-partum to the 30th day of the next pregnancy inclusive (16). The greatest 
exposure to IMI is during the milking phase of the lactation cycle, although new IMI 
occur 7 to 10 times more frequently in the dry period. The highest frequency of new IMI 
is recorded during the early dry period.  IMI decreases during the mid period and 
increases as calving approaches. Nearly all IMI acquired during this period persist into 
the next lactation. At cessation of lactation, changes take place that may increase 
susceptibility to infection. This include (i) the flushing of milk through the teat canal, 
which eliminates colonized bacteria, is stopped (ii) increased internal udder pressure, 
which induces teat canal dilation, allows bacterial penetration and (iii) discontinuation of 
teat dipping, which may lead to the increase of bacterial populations on the exterior skin. 
The increase in infection in the early dry period is transient, since an effective keratin seal 
 15
appears to develop after 10-14 days (24). Degenerative, nonmicrovilliated epithelia of the 
teat cistern mucosa become less prevalent as the udder returns to its normal size 
(involution). Most of the udder pathogens adhere preferentially to the epithelia, leading to 
an enhanced resistance to IMI. During involution, citrate, which competes with 
lactoferrin for iron, is reabsorbed whereas bicarbonate increases in milk; therefore 
conditions for the inhibitory activity action of lactoferrin are optimal (24). 
 
iii) Weather conditions 
The relationship between weather factors and mastitis is difficult to assess, since abrupt 
seasonal changes in weather are accompanied by other changes on the farm. The 
incidence of mastitis appears to be higher in cows just turned out to pasture in wet years 
than in cows in a similar period in dry years. Wet weather thus contributes to the mastitis 
problem (5). There is a higher incidence of mastitis infections during the summer than in 
the cool, dry winter months. Moisture and temperature can have a profound influence on 
yield and nutritive value of crops. Weather could thus have an indirect effect through its 
effect on quality and quantity of pastures. Temperature also has an effect on insect 
populations. Flies are important vectors of bacterial diseases, and biting flies contribute 
greatly to anxiety and unrest in a herd of cows. The effects of heat stress vary among 
breeds of cattle and some cattle are able to adapt to extremes of weather better than 
others. The major effect of heat stress is a decrease in milk production. Cold also 
decreases milk production because of the overall energy demand, reduced blood 
circulation in the mammary gland, and direct effect of cooling on milk synthesis and 
secretion (5). 
 
iv) Age 
The incidence of mastitis increases with age. A more rapid increase per lactation of the 
mild form of the disease is observed in older animals. Susceptibility to mastitis also 
increases with age. Various other factors may also weaken the natural resistance of the 
tissues of older udders to infection (16). 
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CLASSIFICATION OF MASTITIS 
 
Mastitis can be classified into subclinical and clinical forms according to severity, 
duration, distribution, nature of the exudate and primary cause. It can also be classified 
based on aetological, clinical and pathological symptoms and the degree to which the 
udder is affected. A normal quarter shows no outward signs of disease, produces milk 
free of pathogenic organisms and with a SCC of less than 5 x 105/ml (7, 12). 
 
Subclinical mastitis 
The affected udder quarter is characterized by inflammation, but without any visible 
signs thereof. Because of this, infections can persist for months due to the fact that they 
are undetected by the stockmen. The majority of mastitis cases are subclinical. At any 
time subclinical infection can affect up to 50 times more quarters than is evident from 
clinical mastitis. Approximately 70 to 80% of the losses through mastitis could be 
attributed to subclinical mastitis. Milk production of the infected quarter may be 5 to 10% 
lower than normal and the composition of the milk is altered (1, 13). Since subclinical 
mastitis occurs more frequently, this reduction in milk production is economically more 
important than that caused by clinical mastitis. Most cases of subclinical mastitis are 
caused by contagious organisms such as S. agalactiae and S. aureus. Other cases may be 
attributed to environmental organisms such as S. uberis or S. dysgalactiae. The milk 
appears normal, but the SCC is considerably higher (more than 5 x 105/ml milk) with 
pathogenic bacteria and inflammatory products present in the milk. The pH and salt 
content of the milk is also higher (12, 14, 17). 
 
Chronic (recurrent) mastitis  
In this situation the inflammatory process persists for many months, or even from one 
lactation to the next. Chronic mastitis (Fig. 2) is usually clinical, but may establish itself 
in a subclinical form and periodic “flare-ups” are very common. This is very often the 
case with a S. aureus infection (7, 12). 
 
 
 
 
 17
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. A chronic mastitic udder. 
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MASTITIS CONTROL 
 
Mastitis cannot be eradicated and, although it is possible to deal effectively with 
infections caused by some pathogens, little progress has been made in the control of 
others. Total elimination of mastitis is not a realistic goal, but a reduction in the incidence 
of mastitis may be realistic (2). 
 
Control must be based on the prevention of new infection and the elimination of existing 
infections. Programs likely to find acceptance among dairy farmers must be economical, 
practical, effective under most management conditions, and must reduce the incidence of 
clinical mastitis. Possible methods for control include eradication of the causative agent, 
immunization, therapy, breeding resistant cows, or by improved management. However, 
in practice success has been achieved only with the latter (32). 
 
The first practical control methods were based on specific hygienic methods coupled with 
the use of improved antibiotics. This was followed by better designs of milking 
equipment and improved housing. By implementing procedures of postmilking teat 
disinfection and total dry cow therapy with effective antibiotics, it is possible to eradicate 
or reduce infections caused by S. agalactiae and S. dysgalactiae. Control of S. uberis is 
much less affected and coliform mastitis is unaffected. This varying degree of success is 
due to basic differences in the various types of infections. Control of infections caused by 
pathogens that emanate from sources other than the mammary gland, e.g. bedding 
material, is much more difficult (9, 32). 
 
Mastitis infections have similarities, but their differences are distinct, which in turn has 
important consequences for the development of control mechanisms. The pathogens 
emanate from various sources, the period the animal is subjected to exposure of 
pathogens differ, the route of infection differs, and the chances of recovery from an 
established infection varies. Due to the complexity of mastitis infection, we cannot expect 
to discover a single technique to augment or replace control methods currently in place. 
However, by adding to existing control methods, or replacing them with more 
sophisticated (and environmentally safer) medication, mastitis infection may be better 
controlled (2). 
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Drugs used in treatment 
 
1. Penicillins 
The majority of isolates of haemolytic staphylococci from bovine milk samples are 
resistant to penicillin, whereas virtually all species of streptococci are sensitive to the 
antibiotic (7). The activity of penicillin is decreased only slightly in milk. Penicillin is 
well distributed throughout the udder and diffuses relatively well into mammary tissue in 
both normal and mastitic glands, except in large areas of necrosis or fibrosis (30). 
Cloxacillin is a narrow-spectrum, semi synthetic penicillin which is resistant to 
staphylococcal penicillinase. In lactating cows, infusion of cloxacillin is as effective as 
benzylpenicillin against streptococcal and staphylococcal infections. Ampicillin is a 
semi-synthetic penicillin with a broad spectrum of activity which diffuses into the udder 
at higher concentrations than benzylpenicillin (7, 30). 
 
2. Dihydrostreptomycin  
This antibiotic is seldom used on its own in intramammary treatment, but is often used in 
combination with penicillin. Dihydrostreptomycin, one of the aminoglycosides, has a 
basic pH and is unsuitable for systemic treatment of mastitis as it is unlikely that even in 
very high doses it ever reaches therapeutic levels. The aminoglycosides have fairly low 
minimal inhibitory concentrations for staphylococci and for some Gram-negative mastitis 
pathogens, but their activity against streptococci is even lower. The activity of 
dihydrostreptomycin is also markedly decreased in the presence of milk and has a very 
uneven distribution within the udder, taking up to eight hours to become widely dispersed 
throughout the udder parenchyma (7, 30, 37). 
 
3. Tetracyclines 
Oxytetracycline and chlortetracycline are partially inactivated in milk. Injectable 
oxytetracycline has limited bio-availability after being administered intramuscularly and 
does not reach therapeutic levels in milk. Oxytetracycline is a local tissue irritant and is 
very unevenly distributed in normal udder tissue following intramammary injection and 
is therefore not recommended for the treatment of mastitis (7, 30). 
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4. Neomycin 
Neomycin has limited penetration in the udder, which lessens its potential usefulness in 
both parenteral and local treatment of mastitis. However, it is being used as the main 
ingredient in combination drugs for intramammary mastitis therapy because of its wide 
antimicrobial spectrum (7, 30). 
 
5. Erythromycin 
The macrolide antibiotics, which include erythromycin, tylosin, lincomycin and 
spiromycin, pass effectively from the blood into the udder, but their antibacterial spectra 
are limited to Gram-positive pathogens. They are the drugs of choice when attempting to 
eliminate persistent Gram-positive udder infections. In the treatment of acute mastitis 
caused by Gram-positive pathogens, combined parenteral and intramammary application 
is recommended (7, 30, 37). 
 
6. Chloramphenicol 
Chloramphenicol has limited bio-availability when administered intramuscularly and 
should rather be administered intravenously. In certain countries the use of 
chloramphenicol in food-producing animals is strictly forbidden because its use 
constitutes a potential human health hazard (7, 30). 
 
7. Sulphonamides and trimethoprim 
Sulphadimidine, when administered intravenously at the correct dosage is sufficient to 
eliminate both streptococcal and staphylococcal infections. Trimethoprim has a rather 
short half-life which, in cattle, varies between 50 and 100 minutes, thereby limiting its 
application (7, 30). 
 
8. Cephalosporins 
Cephalosporins, which possess broad-spectrum activity against many Gram-negative 
pathogens and beta-lactamase-producing staphylococci, can be used instead of 
combinations of antibiotics. Cephalosporins have a limited distribution in the udder after 
parenteral and intramammary therapy. Cephoxazole is bactericidal and resistant to 
destruction by staphylococcal penicillinase, and by binding to penicillinase produced by 
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Gram-negative bacteria, allows penicillin to act on these otherwise-resistant pathogens. 
Cephoxazole and penicillin have a mutually potentiating effect (7, 30).  
 
9. Metronidazole and clindamycin 
Metronidazole is the only drug that shows consistently good bacteriological activity 
against Bacteroides fragilis. However, there is no intramammary preperation available to 
date that contains metronizadole for mastitis therapy and its efficacy in parenteral 
treatment of mastitis requires further research. Clindamycin is active against anaerobic 
Gram-negative bacilli, such as Bacteroides, Eubacterium and Peptococcus spp. (7, 30). 
 
Studies have shown that 5- or 4-day courses of parenteral therapy produce higher 
bacterial cure rates than 3- and 2-day courses of treatment. Ampicillin penetrates into the 
udder to produce concentrations to inhibit most mastitis pathogens for 24 hours after a 
dose of 20 mg/kg. Doses of 25 mg/kg of cloxacillin and 12.5 mg/kg cephalosporin 
produce effective concentrations for only 4-8 hours. At doses of 12.5 mg/kg, 
erythromycin and tylosin is sufficient to maintain the milk at antibiotic levels greater than 
the MIC’s for staphylococci. For effective levels of streptomycin to be reached in the 
udder, doses of 10-12 mg/kg must be injected every 6 to 12 hours. Penethamate 
hydriodide is hydrolysed in milk to produce benzylpenicillin, and reaches a concentration 
five to seven times greater in milk than in blood. Injectable tetracycline at a dose rate of 
20 mg/kg and amoxycillin/clavulanic acid at 8.75 mg/kg yield adequate concentrations in 
the udder. Preparations using a polyvinypyrrolidone base yield good antibiotic 
concentrations in milk (7, 30). 
 
Antibiotic treatment of mastitis 
 
Clinical cases 
Therapy in clinical cases assists the cow’s defenses to overcome the infection, aids in the 
regression of clinical signs to permit the animal’s milk to be sold, limits udder tissue 
damage and prevents further spread of infection. However, there have been concerns to 
minimize antibiotic residues in milk. This has put pressure on dairy farmers to treat 
clinical mastitis only to produce clinical improvement. Subsequently, the amount of milk 
being discarded are minimized and farmers would also avoid financial penalties for 
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positive antibiotic residue milk test results. These pressures have encouraged the 
marketing of short-duration or even single-dose intramammary treatments. This may lead 
to increased subclinical infection if accompanied by less rigorous application of teat 
disinfection and dry cow therapy; and cost-cutting reductions in the standards of milking 
time hygiene and milking equipment cleaning and maintenance (10, 17). 
 
Dry cow therapy mastitis control program 
Dry cow therapy is presently the most effective means for eliminating infections. 
Products on the market remove between 70 and 98% of infections, depending upon the 
formulation and causative organism. Another value of dry cow therapy is the prevention 
of new infections. Products currently marketed are capable of reducing the new infection 
rate from approximately 14% to 7% of quarters. Persistence of antibiotics in the gland 
provides protection against new infections. Since treatment efficacy of products presently 
available is relatively high, the greatest potential gain could be derived from the 
development of products that would remain in the udder through the first few milkings of 
the next lactation and be more effective in preventing new infections. The antibiotic 
residue would be removed with the colostrum with little risk of contaminating the milk 
supply. These formulations also have a role to play in the prevention of summer mastitis 
in dry cows and pregnant heifers (2, 10).  
 
Lactation therapy 
Therapy during the lactation often is looked upon unfavorably, not only because of an 
inferior effectiveness compared to dry cow therapy, but also because of the economic 
losses associated with discarded milk and udder damage, which may remain throughout 
lactation (27, 37, 44). Treatment response of quarters with clinical mastitis is highly 
variable with positive responses in the range of 40 to 70%. The value of lactation therapy 
in mastitis control is limited further since only 40% of all new infections that become 
clinical are being identified and treated. Subclinical infections have a higher rate of 
response to lactation therapy than do clinical infections. Treatment of subclinical 
infections in early lactation is less successful than treatment later in lactation. Increasing 
the dose of antibiotic during this time usually has no effect on the cure rate. Effective 
therapy of subclinical infections during lactation therefore requires relatively long periods 
of treatment and many countries require that milk from cows under treatment be withheld 
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from sale during treatment (10, 21, 23). Antibiotic treatment of S. aureus mastitis during 
the lactation period is not economically attractive because of the volumes of milk that is 
being discarded, low bacteriologic cure rate, and a lack of economically beneficial 
increase in production following treatment. A program of early identification, culling, 
and segregation is probably the best management approach for controlling these 
infections. Early identification of new infections would allow for early treatment and a 
more favorable response to antibiotics. This may allow the affected quarter to return to 
normal production in the present lactation (10, 17, 23). 
 
Decreasing susceptibility 
Stimulation of the immune response through vaccination should be the ultimate goal if 
complete control is considered essential. However, the large number of different 
organisms causing mastitis makes preparation of an effective vaccine a challenging task. 
Studies have provided evidence that the mammary gland can produce an immune 
response. The greatest economic benefits would be obtained through development of 
vaccines against environmental organisms. There are several management and 
environmental factors related to decreasing susceptibility but are these are usually not 
considered as control procedures. They include the prevention of teat injury, proper 
sanitary care of teat cannulae and treatment materials, and reduction of stress. These 
factors must not be overlooked if maximum benefit is to be gained from control 
procedures (23). 
 
Reasons for failure of mastitis treatment 
 
One of the biggest problems confronting the milk producer is that cows treated for 
mastitis respond poorly or not at all. Many mastitic quarters are treated properly, but after 
2 or 3 weeks mastitis is once again observed in the apparently cured quarter. According 
to Giesecke (1995), reasons for the failure of mastitis treatment resort under four main 
groups, viz.: 
1. Bacterial factors (factors related to bacteria causing mastitis), 
2. Udder pathology (factors related to the damage caused in the udder by mastitis), 
3. Pharmaco-dynamics of mastitis remedies (the properties and action of the mastitis 
remedies administered), 
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4. Poor animal care and veterinary practices. 
 
1. Bacterial factors 
Bacteria such as S. aureus penetrate deep into udder tissue. Additional connective tissue 
is formed and the bacteria are encapsulated. Antibiotics administered reach the bacteria in 
very low concentrations, or not at all. The udder’s connective tissue also has a very weak 
blood supply and even if antibiotics are administered intravenously or intramuscularly, 
the antibiotic concentrations in these tissues are so low that the bacteria are usually not 
killed. Some mastitis producing bacteria produce bacteria without cell walls, while others 
are able to change into forms without cell walls. Thus, antibiotics that inhibit cell wall 
formation are not able to inhibit/kill the bacteria and mastitis treatment fails (11, 37). A 
superinfection of the infected udder with a second mastitis-causing microorganism results 
because of unhygienic practices. The organisms secondarily contaminating the udder 
cause a further infection, because they are not sensitive to the antibiotics with which the 
mastitis was initially treated (11). Antibiotics introduced through the teat canal do not 
necessarily eliminate the bacteria already established in the teat canal. These bacteria 
may again cause mastitis when treatment is stopped. Also, the widespread use of 
antibiotics has raised the question of antibiotic-resistant strains of bacteria. These 
antibiotics only eliminate susceptible organisms while the resistant strains are allowed to 
flourish (11, 37). 
 
2. Blockage of milk tubes, clinical cure and necrosis of the udder tissue 
Udder swelling resulting from mastitis infection closes off the milk tubes. Antibiotics 
applied through the teat canal do not reach the infected udder tissue in sufficient 
concentrations and may thus not kill the bacteria. This may happen despite the fact that 
the bacteria are sensitive to the antibiotics (11, 37). Mastitis treatment is often stopped 
when a clinical cure is observed. If treatment is stopped when a clinical cure is apparently 
achieved, there are still many viable bacteria present in the udder and a repeat attack after 
one to three weeks is very common. Treatment must therefore be continued for the 
prescribed or recommended period. Some mastitis cases are accompanied by necrosis of 
some parts in the udder. This results in a poor blood supply to these areas. Administered 
antibiotics do not properly reach bacteria in these necrotic tissues (11). 
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3. Pharmaco-dynamics of mastitis antibiotics 
Some antibiotics that are used intramuscularly are poorly absorbed and not well 
distributed to the udder tissue. Insufficient concentrations reach the udder and the 
causative organisms are not killed. These antibiotics should preferably be administered 
intravenously (11). Other antibiotics penetrate the blood udder barrier more difficult than 
others. These antibiotics have lower concentrations in the milk and can thus not kill the 
mastitis bacteria efficiently (11, 37). Certain antibiotics have a poor fat solubility and can 
not migrate in sufficient concentrations through tissue to reach the bacteria. The problem 
occurs when insufficient quantities are administered. Connective tissue or abscess 
encapsulation prevents the antibiotics from reaching the bacteria (11, 13). Tetracyclines 
become partially inactive in milk, as they bind with magnesium and calcium. Other 
antibiotics have a very short half-life, and if they are not administered hourly or six- to 
eight-hourly, the concentrations that should be present in the udder for a certain time are 
not maintained and the treatment fails or is ineffective (11). The prime consideration in 
antibacterial treatment of any infectious disease should be given to the host-parasite 
relationship and the effect of the drug on the parasite. Antibiotics alter the balance in 
favor of the host, whose own clearing mechanisms should then be able to eliminate the 
infection. Some antibiotics interfere with the host’s defense mechanisms and are harmful 
to the phagocytic clearing mechanism of the host (37). 
 
4. Poor animal care and veterinary practices 
In case of severe mastitis, the animal may die if very good supportive treatment is not 
given, despite antibiotics being administered. Initial incorrect or inadequate antibiotic 
treatment may result in death, the prognosis being poor or the infection may lead to 
chronic mastitis. If the teat canal is damaged by unhygienic or harsh local mastitis 
treatment, it may result in secondary mastitis over and above the mastitis already present 
(11, 37). 
 
Control of S. aureus infections 
 
Traditionally, treatment has been limited to intramammary infusion of dry cows and 
lactating cows with clinical mastitis. S. aureus is highly resistant to therapy. Quoted cure 
rates for lactating (40%) and dry cows (65%) are suspect, and actual cure rates following 
 26
intramammary infusion may be lower. Explanations for this in vivo resistance include the 
extensive fibrosis and absessation that often follow infection, antibiotic resistance, and 
the conversion of bacteria to cell-wall deficient variants (13, 35). 
 
A promising avenue of therapy for subclinical S. aureus mastitis is the use of antibiotics 
affecting the whole body (systemic antibiotics), either as sole therapy or in conjunction 
with intramammary infusions. The antimicrobial spectrum, distribution properties, and 
long half-life of norfloxacin make this compound a promising candidate for treatment of 
subclinical mastitis. However, this compound is not currently approved for use in food 
producing animals. Estimates of penicillin resistance and beta-lactamase production in S. 
aureus vary widely among surveys (0-82%) and geographical variations are likely. 
Penicillin resistance is associated with decreased cure rates following intramammary dry 
cow therapy and questions have been raised as to whether in vitro resistance or tolerance 
is correlated with in vivo efficacy against S. aureus mastitis (13, 35).  
 
Cell-wall defective L-forms are not recovered or identified using standard milk 
microbiological methods. Cattle harboring these L-forms will be presumptively 
diagnosed as being cured. The likelihood of conversion to L-forms following therapy 
with many antibiotics, the intermittent shedding pattern of cattle infected with S. aureus, 
and the dramatic increase in the numbers of isolates recovered using enrichment 
techniques, raise serious questions concerning reported cure rates. Cure rates have been 
based upon standard microbiologic methods. These methods are likely to miss cattle that 
shed L-forms, intermittently shed bacteria, or shed bacteria in reduced numbers. At least 
one of these three groups of cattle is likely to be an important reservoir of infectious 
bacteria (13, 35). 
 
 
IMMUNIZATION 
 
Vaccination of mastitis is defined as the injection of a suspension of sensitized, 
attenuated, or killed bacteria into the body or udder to induce immunity against the same 
species of bacteria or their toxins. Autogenous vaccines are developed from bacteria 
cultured from the cow to be inoculated, whereas a vaccine made from any other virulent 
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strain/s of the same bacterial species is a stock vaccine. In response to vaccination, a cow 
should develop an antibody titer in the blood and milk against particular bacterial strains 
or their toxins. Also, successful vaccination or immunization should prevent a majority of 
new infections caused by the bacterial strains for which the vaccine was intended (30). 
 
A number of problems are uniquely associated with vaccination of dairy cows against 
mastitis. First, mastitis is usually an immune response of the gland to invasive agents; i.e. 
the disease is equal to the immune response. Therefore, specific enhancement of the 
immune response may exacerbate the disease. Secondly, because of the large volume of 
milk in the udder, there is a dilution of the immune components available to fight 
infection, including immunoglobulins, lymphocytes, phagocytes, and the complement 
system. Similarly, the enormous surface area of the secretory epithelium greatly 
complicates immune surveillance of the gland. Thirdly, milk components, particularly fat 
and casein, greatly reduce the phagocytic and bactericidal activity of phagocytes within 
the milk and gland (37). 
 
The organisms that induce mastitis are numerous and heterogenous. More than 135 
agents responsible for mastitis, most of which are bacteria, have been identified. Because 
there are so many causative organisms and since the opportunities for infection with a 
large variety of these are so great, immunization is difficult (37). 
 
In addition to these difficulties, the success or failure of a mastitis vaccine is often 
difficult to define. Ideally, a vaccine should reduce severity and frequency of mastitis, 
prevent new infections and eliminate existing infections. However, this is more than 
expected of most other successful vaccines, since because most vaccines do little more 
than prevent disease. Recently available vaccines do appear to reduce the incidence of 
clinical disease in a significant and economically efficient manner. Therefore, 
immunization procedures is best seen as adjuncts rather than replacements for traditional 
mastitis control programs (34, 37). 
 
S. aureus mastitis vaccines 
Commercially available bacterial vaccines for S. aureus-induced mastitis are generally of 
dubious efficacy. This is because the vaccines may not be efficient when IMI is the 
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primary criterion. However, vaccination may provide some management advantage by 
increasing spontaneous cure rates, thereby reducing the frequency of subclinical mastitis 
in the herd (30, 34, 37).  
 
Exotoxins or toxoids like β-toxin, leucocidin and α-toxin are usually included in S. 
aureus vaccine preparations. The rationale for this is, that these exotoxins are involved in 
virulence of S. aureus in the mammary gland. In addition, milk and serum antibody titers 
to α- and β-toxins increases significantly in cows infected with S. aureus (30, 34, 37).  
 
Polymorphonuclear neutrophils (PMN) are mainly responsible for eliminating S. aureus 
infections. Protective immunization results in enhanced capacity of the mammary PMN 
and an accelerated PMN response to infection. Elevated opsonic and cytophilic IgG2, but 
not IgG1 antibody, concentrations are necessary for this enhanced PMN activity 
(ruminant PMN lack IgG1 receptors). In addition, certain antigens expressed in vivo, but 
not always under standard in vitro culture conditions, may be important in protection 
from staphylococcal mastitis. At least one of these antigens expressed in vivo appears to 
be an antiphagocytic microcapsule or pseudocapsule (30, 34, 37).  
 
A surface antigen, probably the pseudocapsular material, and perhaps the α- or β-toxins, 
are important protective antigenic components for improved S. aureus mastitis vaccines. 
Most mastitis-inducing strains of S. aureus produce a diffuse polysaccharide slime layer 
or a pseudocapsule. This capsular polysaccharide (CPS) is antiphagocytic, and antibodies 
to the CPS are opsonic. Although antibodies in the serum and milk directed at the 
pseudocapsule could be detected with CPS-enhanced bacterins, infection by S. aureus 
alone, however, do not result in a detectable antibody response to CPS (30, 34, 37).  
 
Approximately 70% of S. aureus strains isolated from bovine mastitis produce CPS 
serologically classified as type 5 or 8. Purified types 5 and 8 CPS are not immunogenic. 
This lack of immunogenicity has led to conjugation of types 5 and 8 CPS to carrier 
proteins. These preparations induce antibody responses to CPS that are of a high titer and 
T-cell dependent. Conjugated CPS, combined with an adjuvant to induce opsonic IgG2 
antibody in the cow, may well provide protection from S. aureus mastitis (30, 34, 37).  
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Another recent approach to provide a vaccine for S. aureus mastitis has been to use one 
of the presumed staphylococcal adhesion proteins as a vaccine. S. aureus has a 
fibronectin-binding protein on its surface that binds to a specific portion of the N-
terminal region of fibronectin, which is one of the specific receptors for its adhesion and 
colonization. rDNA-produced fibronectin-binding protein have been used to immunize 
against S. aureus-induced mastitis. This rDNA-produced fusion protein reduced the 
incidence of clinical mastitis in dairy cows. However, more tests will have to be 
conducted to evaluate the effectiveness of a vaccine based on the fibronectin-binding 
protein or other S. aureus adhesion proteins (30, 34, 37). 
 
A polyvalent S. aureus mastitis vaccine is commercially available in the USA. However, 
immunization with either this product or experimental vaccines does not uniformly 
prevent infection. Since S. aureus mastitis is a contagious udder pathogen, vaccine 
failures are of particular concern. Infected cattle will remain a potential reservoir of 
contagious bacteria. Use of this or similar products may provide a useful adjunct to 
traditional control programs. Any benefits likely will be the greatest in herds with a high 
prevalence of infection and a high incidence of peracute mastitis in which eradication is 
not practical. This vaccine apparently provides no protection against infection by other 
staphylococcal species  (30, 34, 37). 
 
 
IMMUNOTHERAPY 
 
A family of glycoproteins responsible for the regulation of leukocyte proliferation, 
maturation and release into the peripheral blood have been recognized, isolated, and 
characterized. Collectively, these glycoproteins are termed colony stimulating factors 
(CSF). Among this class of compounds are the neutrophil (granulocyte) colony 
stimulating factor (GCSF), the macrophage colony stimulating factor, and the 
granulocyte-macrophage colony stimulating factor (GMCSF) (34). 
 
Parenteral injection of exogenous CSF has caused profound neutrophilia within two days 
that persisted for three days following the termination of CSF administration. Although 
dramatic increases were observed in peripheral blood neutrophil counts, only modest and 
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statistically marginal increases in milk somatic cell counts were observed in CSF-treated 
cows. A decreased rate of IMI has also been observed following the challenge with S. 
aureus in cows pretreated with GCSF. GCSF-treated cows also had a shortened duration 
of IMI with Klebsiella pneumoniae following experimental infection. However, in these 
studies small numbers of cows were used and further studies are needed before 
conclusions may be drawn concerning the possible therapeutic role of these compounds 
(34). 
 
No leukopoietic factor is approved for use in lactating dairy cattle. A variety of other 
agents, including levamisole, thiabendazole, avridine, isoprinosine, glucan, and ascorbic 
acid have been investigated as potential immunotherapy agents in cattle. Although 
several agents have demonstrable effects on in vitro measurements of immune response 
function, none of the aforementioned agents has demonstrated clear efficacy in either the 
treatment or prevention of bovine mastitis. Although no immunostimulant of 
demonstrated efficacy is available for mastitis treatment and control, it remains an active 
field of study and efficacious immunostimulants may become available in the near future 
(34). 
 
Intramammary devices 
 
Intramammary devices (IMD) have been investigated as a means by which leucocytosis 
could be induced in culture-negative mammary glands. In one study, insertion of a 
smooth polyethylene IMD in lactating dairy cows, resulted in a rapid, transient increase 
in milk SCC that subsided within 1 week to SCC concentrations 50% higher than either 
the pre-insertion concentrations or concentrations observed in control quarters. Similar 
increases in milk SCC were not observed when the IMD was inserted at drying off. The 
observed increase in SCC was associated with an increased resistance to experimental 
infection. Most IMD designs successfully induce a milk leukocytosis but quarters with 
IMDs have prominent histologic changes. Quarters treated with some IMD models also 
have significant decreases in milk production. In subsequent studies, insertion of several 
IMD models induced a milk leukocytosis, but only one device was deemed protective 
against IMI (34). 
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INTRODUCTION 
 
Lactic acid bacteria (LAB) are united by morphological, metabolic and physiological 
characteristics (100). They comprise a diverse group of Gram-positive, anaerobic, 
microaerophyllic or aero-tolerant nonspore-forming bacteria. They occur as cocci or rods 
and lack catalase, although pseudo-catalase has been found in rare cases (118). They are 
fastidious, non-motile, acid tolerant, devoid of cytochromes and do not reduce nitrate. 
They are chemo-organotrophic and grow only in complex media. Fermentable 
carbohydrates are used as energy source. Hexoses are degraded mainly to lactate 
(homofermentative metabolism) or to lactate and additional products such as CO2, 
formate, succinate as well as acetate or ethanol depending on whether aerobic or 
anaerobic conditions prevail (heterofermentative metabolism) (100, 117, 118). Recent 
taxonomic revisions suggest that LAB comprise the following genera: Aerococcus, 
Alloiococcus, Bifidobacterium, Carnobacterium, Enterococcus, Lactobacillus, 
Lactococcus, Leuconostoc, Melissococcus, Oenococcus, Pediococcus, Streptococcus, 
Tetragenococcus, Vagococcus and Weissella (21, 100, 118).  
 
LAB are widely distributed in nature. They exist on plant surfaces, in plant decaying 
material, food products such as milk, fermented meat and vegetables, fish, sour dough, 
silage and beverages and in the gastrointestinal, genital and respiratory tracts of man and 
animals, manure and sewage (117, 118). 
 
Some of these environments are rich in nutrients and energy sources and thus excellent in 
supporting the growth of other microorganisms. Because of this, LAB have developed 
strategies to efficiently compete with other organisms (100). This includes the production 
of growth-inhibiting substances and large quantities of lactic acid. Peptide antibiotics, 
antibiotic-like substances, bacteriocins and bacteriocin-like substances are also produced. 
The production of these antimicrobial proteins is the reason why LAB are so important in 
the food and feed technology, where they may be used to inhibit the growth of food-
spoilage bacteria (21). Other applications of LAB have been directed towards probiotics. 
Probiotics involve the prophylactic use of microorganisms to help protect the host animal 
from diseases (100). 
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ANTAGONISM OF LACTIC ACID BACTERIA TOWARDS 
PATHOGENIC BACTERIA 
 
Lactic acid bacteria may help promote health and combat the proliferation of bacterial 
pathogens. The following factors may be involved: 
 
1. Competitive exclusion 
This theory proposes the prevention of colonization of some microorganisms (including 
pathogens) by others. The beneficial bacteria occupy adhesion sites in the gut that would 
otherwise be populated by harmful bacteria. The precise mechanism involves specific 
recognition of receptor sites (oligosaccharides) by bacterial fimbrae (lectins). Other 
mechanisms include competition for nutrients, reduction of the redox potential and non-
specific activation of the immune system (29). Competitive exclusion can take place 
throughout the digestive tract when non-pathogenic organisms such as lactic acid-
producing bacteria are present in food. The LAB migrate from the stomach into the small 
intestine where the production of lactic acid may mediate, at least in part, the inhibition 
of the development of pathogenic bacteria. Competitive exclusion could also be as a 
result of aggregation of non-pathogens to pathogens, preventing binding to attachment 
sites and leading to their removal from the gut (29). 
 
2. Reduction of toxic amine production 
Metabolic activity of the intestinal micro-flora produces amines and ammonia that may 
have deleterious effects on the host. Amines are associated with diarrhea in that it 
increases peristalsis. The level of amines produced within the gut can be reduced by 
lactobacilli, e.g. L. acidophilus (29). 
 
3. Interactions with bile 
Bile salts are surface-active chemicals that aid digestion by forming polymolecular 
aggregates with water-insoluble lipids and fat-soluble vitamins. Bile is important in 
blocking the passage of many live organisms into the lower intestine and inhibits the 
growth of enteric anaerobic bacteria. Specific strains of lactobacilli can release free bile 
acids into the intestinal tract and could thus influence the balance of the intestinal 
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bacteria. Unconjugated (free) bile acids are much more inhibitory than conjugated forms 
(29). 
 
4. Anti-enterotoxic activity 
Toxins produced by pathogens bind to epithelial receptors and prevent the colonisation of 
bacteria. Enterotoxins, produced by a number of E. coli strains, that causes fluids to be 
lost from the intestine, can be neutralised by probiotic bacteria. Anti-enterotoxic activity 
has been recorded for certain strains of L. bulgaricus and E. faecium (29). 
 
5. Stimulation of immunity 
LAB may stimulate the production of antibiotics and phagocytic activity against 
pathogens in the intestine and other tissues of the body. Bacteria contain some common 
antigens that can cross react with some pathogenic microorganisms and thus immunize 
against an invasion of pathogenic microorganisms (29). 
 
6. Antimicrobial substances 
Since LAB are found in widespread environments, they have developed methods to 
inhibit the growth of competitive organisms. Fermented foods preserve well because of 
the souring effect that LAB imparts to the food by the conversion of sugars to organic 
acids (109). LAB are also capable of producing inhibitory substances other than organic 
acids that are antagonistic towards other micro-organisms. These substances are produced 
in much smaller amounts and include bacteriocins, hydrogen peroxide, diacetyl, volatile 
fatty acids and secondary reaction products such as hypothiocyanite generated by the 
action of the enzyme, lactoperoxidase, on hydrogen peroxide and thiocyanite (11, 109). 
 
7. Hydrogen Peroxide 
Accumulation of hydrogen peroxide can occur because LAB do not possess catalase. 
Hydrogen peroxide is produced by several LAB species, including lactobacilli, lactococci 
and pediococci and it inhibits the growth of many bacteria, especially pathogenic Gram-
negative types. The antimicrobial effect of H2O2 is based on its oxidative properties that 
results in irreversible changes in the microbial cell membrane. Peroxide has been 
implicated in the inhibition of Staphylococcus aureus. It can react with other components 
to form inhibitory substances. In raw milk, hydrogen peroxide can react with endogenous 
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thiocyanate, which is then catalyzed by lactoperoxidase to form intermediary oxidation 
products inhibitory to microorganisms. These oxidation products can inhibit bacterial 
growth, and may be bactericidal at a low pH. This is called the lactoperoxidase 
antibacterial system (29, 40, 109). 
 
8. Diacetyl 
Diacetyl (2,3-butanedione) is a metabolic end product of LAB that is synthesized from 
the intermediary metabolic pyruvate. It is best known for the buttery aroma that it imparts 
to cultured dairy products. The compound is produced by a variety of genera, including 
Lactococcus, Leuconostoc, Lactobacillus and Pediococcus. Lactococcus lactis subsp. 
lactis biovar diacetylactis and Leuconostoc spp. can use citrate in milk to produce 
diacetyl. Diacetyl is inhibitory to yeasts and Gram-negative bacteria at a level of 200 
μg/mL. A level of 300 μg/mL is inhibitory to non-lactic Gram-positive bacteria. LAB are 
not inhibited at concentrations ≤350μg/mL (40, 109). 
 
9. Acetaldehyde 
Acetaldehyde is produced in certain dairy fermentations, notably yogurt, where it arises 
from the activity of the enzyme threonine aldolase in L. bulgaricus. This enzyme cleaves 
threonine into acetaldehyde and glycine. 44ppm of acetaldehyde are able to inhibit cell 
division in E. coli (109). 
 
 
BACTERIONS PRODUCED BY LAB 
 
Bacteriocins can be defined as biologically active proteins or protein complexes (protein 
aggregates, lipocarbohydrate proteins, glycoproteins, etc.), displaying a bactericidal mode 
of action towards genetically closely related species (21). However, recently the 
inhibitory spectrum of these molecules has been widened to include various Gram-
negative bacteria and food pathogens (109). Bacteriocins form a heterogenous group with 
respect to the bacterial species responsible for its production, molecular size, physical and 
chemical properties, stability, antimicrobial spectrum, mode of action (21). 
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Klaenhammer (1993) defined four distinct classes of LAB bacteriocins: Class I: 
lantibiotics, Class II: small (<10kDa) heat-stable membrane-active peptides, Class III: 
large (>30kDa), heat-labile proteins, and Class IV: complex bacteriocins. Class II 
bacteriocins were further divided into Listeria-active peptides with an N-terminal 
consensus sequence (Class IIa), poration complexes requiring two different peptides for 
activity (Class IIb) and thiol-activated peptides that require reduced cysteine residues for 
activity (Class IIc). Currently, bacteriocins are classified as follows (Moll et al., 1999; 
Nes et al., 1996). Class I (lantibiotics), which is further divided into type A lantibiotics 
and type B lantibiotics. Type A lantibiotics are elongated, cationic, pore forming 
peptides. Type B lantibiotics are compact, with globular structures, are enzyme inhibitors 
and are immunologically active. Class II, the small heat-stable non-lanthionine peptides, 
is divided into four groups. Class IIa consists of Listeria-active peptides with an N-
terminal consensus sequence. Class IIb are two-peptide bacteriocins. Class IIc contains 
sec-dependant bacteriocins, and Class IId contains the small heat-stable non-lanthionine 
bacteriocins that do not belong to any of the three groups within Class II. Class III 
consists of large heat labile bacteriocins (73). Most of the bacteriocins belong to Class I 
or II and most of the research has focussed on these two classes (79). 
 
Bacteriocins produced by LAB either have a bactericidal or bacteriostatic effect on 
sensitive cells, eventually resulting in cell death. The primary target of bacteriocins 
produced by LAB is the cytoplasmic membrane. These peptides initiate reactions altering 
the membrane permeability which disturbes membrane transport or dissipating the proton 
motive force. Because of this, energy production and the biosynthesis of proteins or 
nucleic acids are inhibited (21). 
 
Bacteriocins are either chromosomally or plasmid encoded and many bacteriocin 
determinants appear to be organized in an operon. It has been postulated that the 
immunity gene, encoding the immunity protein in the bacteriocin-resistant producing cell, 
forms part of the bacteriocin operon. Furthermore, most of the bacteriocins are produced 
as precursor proteins (pre-peptides) with helical N-terminal extensions of 18-24 amino 
acids, which are removed post-translationally to yield the mature bacteriocin. The leader 
peptide is cleaved off prior to excretion into the microbial environment of the mature 
peptide. The leader peptide serves as recognition signal and directs the prebacteriocin to 
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the ABC transporter. Furthermore the leader peptide renders the bacteriocin inactive 
inside the cell (21) 
 
From an application viewpoint bacteriocins have an interesting potential. They could be 
used as specific markers in epidemiological studies and as prophylactic tools. The genes 
of bacteriocin production and immunity could be used for the development of food-grade 
cloning vectors, which would selectively be retained within the bacterial population. 
Bacteriocins may also be used food preservatives (21). 
 
 
Bacteriocins produced by Enterococcus spp. 
 
Enterococci belong to the clostridial subdivision of Gram-positive bacteria, together with 
the other genera of LAB. Since 1984, chemotaxonomic and phylogenetic studies have 
resulted in the assignment of 19 species to the genus (32). They constitute a large 
proportion of the autochthonous bacteria associated with the mammalian gastrointestinal 
tract (GIT). In humans they have also been isolated from the urinary and hepatobiliary 
tracts and the vagina. They are among the first group of bacteria colonizing the microbial 
ecosystem in ruminants. Other sources include raw milk, soil, surface waters, plants and 
vegetables. In food they occur in meats because of contamination by enterococci in the 
GIT at the time slaughter. They are also found in a variety of cheeses, especially artisanal 
cheeses produced in Southern Europe and Mediterranean countries (32, 101). 
 
Enterococci produce a wider variety of antimicrobial peptides than has been described for 
strains of most other LAB genera. Bacteriocins produced by Enterococcus spp. belong to 
class II although some have been characterized as class I or cyclic enterocins (30, 32). 
However, several bacteriocins produced by Enterococcus faecium and Enterococcus 
faecalis such as enterococcin Sf25, enterocin 81, enterocin 01, enterocin EJ97, enterocins 
1071 A an 1071B, and enterocin 012 either do not belong in any of the currently 
described groups, or have not been fully characterized (60). Bacteriocins of some strains 
of E. faecalis are encoded by pheromone responsive conjugative plasmids. All enterocins 
share a number of common characteristics such as heat stability, stability over a broad pH 
range and antimicrobial activity towards Listeria monocytogenes (101). The anti-Listeria 
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activity may be explained by the fact that enterococci and listeriae are phylogenetically 
closely related (32). 
 
Enterococcus casseliflavus EC24, E. faecium CCM 4231 and E. faecium AL86 produce 
bacteriocins with a broad antimicrobial spectrum including some Gram-negative species. 
The peptides are heat stable, sensitive to proteolytic enzymes and remain active even 
after storage at –20oC and/or –80oC. Optimum production was recorded during 
exponential growth and between pH 4.5 and 7.0 they are bacteriostatic against listeria 
(62). 
 
Bacteriocins from E. casseliflavus strains EC4, EC32, EC5, EC2, Enterococcus sp. EV10 
and E. faecalis strains V24, V6, ES49, EF22, isolated from cattle dung water and/or -
waste, have a broad spectrum of activity including acivity against Escherichia coli 
isolated from the hemorrhagic uremic syndrome of children (62). 
 
E. faecium strains EK13 and AL41 produce small peptides that are heat-stable, with 
optimum production between pH 5.5 and 6.5. Their antimicrobial spectrum includes 
Bacillus cereus, Enterococcus avium, E. caselliflavus, E. faecalis, E. faecium, 
Enterococcus sp., Listeria innocua, L. monocytogenes, Micrococcus luteus, 
Staphylococcus aureus, Staphylococcus chromogenes, Staphylococcus lentus, 
Staphylococcus vitulinus, Staphylococcus xylosus and Streptococcus bovis (62). 
 
E. faecalis V24 produces a bacteriocin-like substance active against strains of 
Enterococcus durans, Enterococcus malodoratus, E. casseliflavus, E. faecium, E. 
faecalis, S. aureus, S. xylosus, L. monocytogenes and Gram- negative bacteria such as 
Shigella sp., Salmonella sp. and Enterobacter cloacae. The substance remains stable for 
one week at both room temperature and –20oC. A decrease in activity up to 20000 AU/ml 
is noted at –80oC. Bacteriocin activity is not affected by catalase and decreases after 
treatment with hydrolytic enzymes, but is not lost. The peptide is resistant at 37oC for 24 
h, and at 60oC for 1 h. Activity is also retained after boiling for 30 min and is stable from 
pH 4 to 7 (61). 
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E. faecalis strains BFE 1113, BFE 1229 and BFE 1263 isolated from the faeces of 
minipigs all produce a group II bacteriocin. These strains display a narrow range of 
antimicrobial activity, mainly towards other enterococci. Enterocin production starts 
during early exponential growth and maximum production is recorded at the beginning of  
the stationary phase. The enterocin is sensitive to α-chymotrypsin, proteinase K, pronase, 
trypsin, papain and pepsin but are not affected by lipase, lysozyme and catalase. Low 
levels of bacteriocin activity are retained after 15 min at 121oC. The enterocin remain 
active from pH 2.0 to 11.0 and bacteriocin levels are highest in a pH range from 6.0 to 
8.0. The molecular weight of the bacteriocin is 3.4 kDa and a bactericidal mode of action 
is displayed towards sensitive cells (22). 
 
Bacteriocins JBL1061, JBL1083 and JBL1351 produced by E. faecium strains JBL1061, 
JBL1083 and JBL1351 respectively, are active against several Gram-positive bacteria, 
including strains of E. faecalis, E. faecium, Lactococcus lactis subsp. cremoris, 
Lactobacillus sakei and L. monocytogenes. The inhibitory spectra of the three 
bacteriocins are relatively similar and with the exception of partial inhibition of strain 
JBL1061 by JBL1351, the bacteriocins have little effect on each other, suggesting that 
the bacteriocins may be identical. The antilisterial activities of the bacteriocins were not 
significantly affected by RNase, catalase, heat (100oC, 30 min) or pH, whereas all three 
were slightly sensitive to chloroform. The bacteriocins are digested by β-chymotrypsin, 
ficin, pronase E, proteinase K and trypsin, but not pepsin. Antilisterial activity was also 
retained after storage at –20oC and 4oC at pH 4.5 and 6.8 for at least 3 months and at 
37oC for 24 h at pH 4.5 and 6.8. The apparent absence of plasmids in JBL1061 and 
JBL1083 suggests that the genes for bacteriocin production and immunity are located on 
the chromosome of strains JBL1061 and JBL1083. Although strain JBL1351 does 
possess a plasmid, the genetic determinants related to the listericidal activity are yet to be 
localized. This listericidal effect is, however, not accompanied by lysis of the cells (2). 
 
E. faecium strains RZS C5 and RZS C13, isolated from cheese and silage, respectively, 
produce bacteriocins active against L. monocytogenes and L. mesenteroides subsp. 
dextranicum. Weak inhibition was also measured against Clostridium butyricum and 
Clostridium perfringens. The antimicrobial activity was completely lost after incubation 
with trypsin, α-chymotrypsin, pronase E and proteinase K. With pepsin, activity was lost 
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partly. Strain RZS C5 contains a 4 kb plasmid, while strain RZS C13 contains a 23 kb 
plasmid. Heating for 15 min at 100oC at pH 4.5 reduced the residual activity by at least 
50%. A similar reduction is encountered at pH 6.5, while this is even more pronounced at 
pH 8.5. Both bacteriocin preparations remained stable, independent of the pH or the 
storage temperature for at least 14 days. The molecular weight of the two bacteriocins is 
estimated at ± 3.0 kDa (115). 
 
E. faecium S-34 produces a bacteriocin of 30 kDa (66). E. faecalis E23 produces a 
bacteriocin with a molecular mass of 290 kDa (66). E. faecalis 226 produces a 
bacteriocin that is encoded on a 5.2 kb conjugative plasmid (33). 
 
Enterocins L50A and L50B 
These novel bacteriocins are produced by E. faecium strains L50, 6T1a and BFE 1072 
(32). Enterocins L50A and L50B resemble the two-peptide bacteriocins of class IIb (22). 
The bacteriocins are not post-translationally modified and do not require the presence of 
a leader or signal peptide for secretion. Each peptide has antimicrobial activity on its 
own, with enterocin L50A being more active. However, when acting together synergistic 
activity is shown (14, 32). Enterocins L50A and L50B display a broad antimicrobial 
spectrum, which includes foodborne pathogens, such as Clostridium botulinum C. 
perfringens, L. monocytogenes, S. aureus, B. cereus, as well as human and animal 
pathogens such as Streptococcus pneumoniae, Streptococcus oralis, Streptococcus 
parasanguis and Streptococcus agalactiae (13). The bacteriocins share homology with 
the staphylococcal haemolysins, yet they do not show haemolytic activity (22, 32). 
Bacteriocins L50A and L50B have a bactericidal, mode of action and are encoded by a 50 
kb plasmid, pCIZ1 (26). The mature L50A peptide contains 44 amino acids with a 
molecular mass of 5190 Da, while peptide L50B contains 43 amino acid with a mass of 
5178 Da (32). E. faecium L50 also produce enterocins P and a novel unmodified non-
pediocin-like bacteriocin termed enterocin Q. In this strain enterocin P is encoded by the 
same plasmid pCIZ1 that encodes enterocin L50. Enterocin Q is encoded by a second 
plasmid, pCIZ2, and consists of 34 amino acids with a molecular mass of 3980 Da. The 
bacteriocin is also synthesized without an N-terminal leader sequence or signal peptide. 
Antimicrobial activity is lost by protease treatment, but the peptide withstands 100oC for 
5 min. Bacteriocin production by E. faecium L50 showed that enterocins P and Q are 
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produced in the temperature range from 16oC to 47oC. Maximal production is at 47oC for 
enterocin P and between 37oC to 47oC for enterocin Q. Enterocins L50A and L50B are 
maximally synthesized at 16oC to 25oC and are not detected at 37oC or above. E. faecium 
27 which harbours both plasmids contains the structural genes for enterocins L50A and 
L50B as well as enterocin P and Q (13). E. faecium B2, isolated from Malaysian tempeh, 
produce a bacteriocin termed enterocin B2, which is identical to enterocin L50, although 
the structural genes encoding the bacteriocins are chromosomally located (74). 
 
Enterocin P 
The bacteriocin is produced by E. faecium P13, isolated from Spanish dry-fermented 
sausage, and other related strains (12, 45). Enterocin P is an amphipatic, cationic 
pediocin-like peptide composed of 44 amino acids and has a molecular weight of 4493 
Da (32, 44, 74). The structural gene of enterocin P is located chromosomally and the 
bacteriocin is secreted via the sec system. Enterocin P is classified as a Class IIc 
bacteriocin (32, 74). The bacteriocin is unique in having both the consensus sequence 
YGNGVXC and a wide bactericidal inhibitory spectrum against foodborne Gram-
positive pathogenic bacteria, including S. aureus and L. monocytogenes as well as 
organisms such as Pediococcus acidilactici, Pediococcus pentosaceus, Staphylococcus 
carnosus, Lactobacillus curvatus, Lactobacillus fermentum, L. sakei, L. lactis, E. 
faecalis, E. faecium, L. innocua, B. cereus, C. perfringens, C. botulinum and 
Propionibacterium sp (26, 45). Depending on the buffer used, enterocin P dissipates the 
transmembrane potential. The bacteriocin efficiently elicits the efflux of potassium ions, 
but not of intracellularly accumulated anions like phosphate and glutamate. This indicates 
that enterocin P forms specific, potassium ion-conducting pores in the cytoplasmic 
membrane of target cells (45). Maximum antimicrobial activity is obtained during late 
logarithmic growth with a drop during stationary growth. No decrease in activity is 
detected after 5 days at 16oC. Enterocin P is protease sensitive. The peptide retains 
activity after exposure to heat of 100oC for 60 min and 121oC for 15 min and can 
withstand exposure to pH values between 2.0 and 11.0, freeze thawing, lyophilization and 
long-term storage at 4 and –20oC (12). Other enterocin P-producing strains are E. faecium 
AA13 and E. faecium G16 (13). E. faecium B1, isolated from Malaysian tempeh produce 
a bacteriocin termed enterocin B1 identical to enterocin P (74). 
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Enterocins A and B 
The bacteriocins are produced by E. faecium strains WHE 81, CTC492, T136, BFE  900, 
BFE 1170 and BFE 1228. Strains WHE 81 and CTC492 were isolated from Muster 
cheese; strain T136 from fermented Spanish sausage; strain BFE 900 from black olives 
and strains BFE 1170 and BFE 1228 from the faeces of minipigs. Enterocin A is a class 
IIa, pediocin-like bacteriocin with a molecular weight of 4833 Da and a pI of 9.07 (5, 10, 
27, 32). The bacteriocin remains active from pH 4.0 to 9.0. (28). The antimicrobial is 
translated as a prepeptide of 65 residues, which is then processed to yield a mature 
bacteriocin of 47 residues. The 18-residue N-terminal extension is a typical double-
glycine leader sequence (27). Enterocin B is a small nonpediocin-like class IIc 
bacteriocin (5, 32, 76). The bacteriocin is secreted sec-independently and is a one-peptide 
bacteriocin lacking the YGNGVXaaC-motif. The bacteriocin’s prepeptide includes a 53-
residue sequence and a double-glycine leader sequence of 18 residues in the putative N-
terminus. Enterocin B has a molecular weight of 5462.2 Da and a pI of 9.25 (5, 27, 32). 
The bacteriocin is heat stable and retained some activity after incubation at 100oC for 20 
min. Bacteriocins A and B are bactericidal and inhibit spoilage and foodborne pathogens 
such as Clostridium tyrobutyricum, Clostridium sporogenes, Propionibacterium spp., L. 
monocytogenes, and S. aureus (10, 27). Production of enterocins A and B is regulated by 
an internal induction factor, enterocin F (5). The genes encoding enterocins A and B are 
chromosomally located. The enterocins produced by E. faecium strains T136 and 
DPC1146, isolated from Spanish fermented sausages, and E. faecium BC25, isolated 
from the rumen of a cow, are suspected to be identical to enterocin A (27, 76). 
  
Enterocin CCM 4231 
The bacteriocin is a small, thermostable hydrophobic substance with a broad 
antimicrobial spectrum against Gram-positive bacteria, including L. monocytogenes and 
Gram-negative bacteria. Enterocin CCM 4231 is produced by E. faecium CCM 4231 (58, 
59). The bacteriocin controlled L. monocytogenes in experimentally contaminated dry 
fermented Hornád salami and exhibited an anti-listerial effect during Saint-Paulin cheese 
manufacture (59, 63). Enterocin CCM 4231 lowered the counts of enterococci and 
staphylococci significantly in a cattle slurry environment, while counts of E. coli, listeriae 
and pseudomonads were also decreased (60). The bacteriocin was able to eliminate 
enterococci and staphylococci in “bryndza”, while a reduction in E. coli was also noted. 
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The level of experimentally innoculated L. innocua strain was also reduced, although not 
completely inhibited (57). The inhibitory effect of enterocin CCM 4231 have also been 
used to control the growth of L. monocytogenes and S. aureus in soy milk, although the 
latter was not fully inhibited. The inhibitory effect against L. monocytogenes was 
bactericidal, while S. aureus was influenced bacteriostatically (58). The inhibitory effect 
of enterocin CCM 4231 has also been observed in environments such as the rumen fluid 
(60). 
 
Enterocin 1146 
E. faecium DPC 1146 produces enterocin 1146 active against L. monocytogenes, L. 
innocua and L. sakei. Enterocin 1146 has a bactericidal mode of action. The bacteriocin 
is produced during late logarithmic growth and the highest antimicrobial activity is 
obtained after 6 h of fermentation at 37oC (21, 33). The optimal pH for enterocin 1146 
production is 5.5 (96). Enterocin 1146 samples lose activity rapidly at 37oC and the 
activity also decreases after 30 min at 80oC and 100oC (21, 22). The activity is stable for 
long periods (months) at –20oC. The bacteriocin is sensitive to pronase E, pepsin, trypsin, 
α-chymotrypsin and proteinase K, but insensitive to catalase (21). Enterocin 1146 has a 
molecular mass of 3000 Da and can thus be classified as a low molecular weight 
bacteriocin (21, 115). Heating above 60oC causes partial or total loss, depending on the 
pH of the enterocin preparation. The bacteriocin is more stable at acid pH. Inactivation at 
neutral or alkaline pH is partially reversible. Elimination of the only plasmid present in E. 
faecalis DPC 1146 do not affect production and immunity of the bacteriocin, which could 
indicate that these traits are either chromosomally encoded or present on a stable but 
undetectable plasmid (21). 
 
Enterocin ON-157 
E. faecium NIAI 157, isolated from plant materials such as silages and fermented 
vegetables, produces enterocin ON-157 which is inhibitory towards strains of 
Lactobacillus plantarum, L. sakei, E. faecalis, E. faecium, E. hirae, L. mesenteroides, P. 
acidilactici, P. pentosaceus and L. monocytogenes. Enterocin ON-157 is produced during 
logarithmic growth with maximum yield during stationary growth, which is after 6h at a 
pH of 5.4. Bacteriocin activity is stable at 30oC for 1 h at pH range 2 to 7. However, the 
activity is unstable at 100oC for 30 min at pH 6 to 7, while it is stable at pH 2 to 5 under 
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the same conditions. Activity is completely inhibited by α-chymotrypsin and pepsin and 
partly inhibited by pronase and trypsin. Activity is also completely inhibited by α-
amylase and partly by α-glucosidase. Enterocin ON-157 is associated with a 49 kb 
plasmid (pEN100) and has a molecular weight of 2500 Da. The bacteriocin has a 
bactericidal mode of action and is described as a glycoprotein (82). 
 
Enterocin I 
This novel bacteriocin is produced by E. faecium 6T1a, a strain originally isolated from a 
Spanish-style green olive fermentation. Enterocin I is active against strains of 
Lactobacillus, Propionibacterium, Clostridium, Bacillus, E. faecalis, L. lactis, P. 
pentosaceus, L. monocytogenes and L. innocua. The bacteriocin is stable at 100oC for 5 
min, but was partially inactivated by autoclaving. The inhibitory activity is abolished 
after treatment with α-chymotrypsin, pronase E, proteinase K, subtilopeptidase A, 
thermolysin and trypsin. Other enzymes such as α-amylase, catalase, ficin, lysozyme and 
RNase A, however, did not affect the activity. Maximum inhibitory activity is observed 
during early stationary growth. Enterocin I consists of 44 amino acids and has a 
molecular size of 5 kDa. Bacteriocin production and immunity are encoded by plasmid 
pEF1 (18). However, enterocin I is identical to enterocin L50 (66). 
 
Enterocin 01 
E. faecium NA01, isolated from “wara”, produces enterocin 01 which is inhibitory 
towards Lactobacillus viridescens, L. sakei, Listeria welshimeri, L. monocytogenes, L. 
innocua, L. lactis subsp. lactis and E. faecalis. The bacteriocin is inactivated by α-
chymotrypsin and proteinase K, but not by trypsin and pepsin. The inhibitory activity is 
stable at 100oC for 5 min and at pH 2.0 to 6.0. However, heating for a longer period at 
this temperature results in inactivation (85). Production of enterocin 01 is encoded on a 
plasmid (33). 
 
Bacteriocin 7C5 
E. faecium 7C5 produces bacteriocin 7C5, which inhibits the growth of L. monocytogenes 
on the surface of Tallegio cheese (101). The peptide is inactivated by α-chymotrypsin, 
proteinase K and trypsin. Bacteriocin 7C5 is heat stable and is produced during late 
logarithmic growth. The bacteriocin has a weak stability at pH 5.0 (33). 
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Bacteriocin RC714 
The vancomycin-resistant E. faecium RC714, isolated from a human exudate sample, 
produces bacteriocin RC714. The bacteriocin shows inhibitory activity against Listeria 
murrayi, Listeria grayi, L. monocytogenes, L. innocua, Lactobacillus paracasei, L. 
plantarum, E. faecalis, E. faecium, P. pentosaceus and Leuconostoc sp. The bacteriocin is 
resistant to heat (100oC for 20 min) and is stable from pH 3 to 11. Bacteriocin RC714 is 
susceptible to trypsin, α-chymotrypsin, papain, alkaline protease and proteinase K, but 
resistant to lysozyme. Bacteriocin RC714 is a class II bacteriocin. According to the 
amino acid sequence, bacteriocin RC714 is 88% homologous and 92% similar to 
bacteriocin 31 from an E. faecalis strain. A difference of 5 out of 42 amino acids with 
respect to bacteriocin 31 is observed. On this basis bacteriocin RC714 could represent a 
new enterocin different from bacteriocin 31 (20). 
 
Enterocin CRL 35 
E. faecium CRL 35, isolated from a regional cheese, produces a pediocin-like Class IIa 
bacteriocin, termed enterocin CRL 35. The bacteriocin has a molecular weight of 3500 
Da and is inhibitory towards foodborne pathogens, including L. monocytogenes. 
Enterocin CRL 35 also has antiviral activity against thymidine-kinase (tk+) and deficient 
(tk-) strains of herpes simplex (HSV) type 1 and 2 in Vero and BHK-21 cells. The 
compound inhibits viral multiplication and has no virucidal effect. Antibacterial activity 
is destroyed by incubation with protease IV or drastic treatment such as raising the pH to 
a value of 13 or heating at 100oC for 10 min (116). 
 
Enterocins EIA and EIB 
The bacteriocins are produced by E. faecium strain EI and are active against certain 
strains of enterococci, Streptococcus salivarius, Clostridium septicum, C. perfringens and 
L. monocytogenes (55). Enterocin EIA is pepsin-sensitive, while enterocin EIB is 
resistant to trypsin (21, 55). The MW for EIB is greater than 4000 Da and about 10 kDa 
for EIA (115). The action of purified enterocin EIA and EIB is primarily bactericidal, but 
is not accompanied by cell lysis (55). 
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Enterocin 81 
E. faecium WHE 81, isolated from cheese, produces enterocin 81 which is inhibitory 
towards certain enterococcal strains, Listeria seeligeri, L. monocytogenes, L. innocua and 
L. plantarum. The bacteriocin has a bactericidal, but not bacteriolytic, mode of action. 
Enterocin 81 is completely inactivated by α-chymotrypsin, ficin, nagarse, pepsin, pronase 
E, proteinase K and trypsin, but not by catalase. The bacteriocin is equally active at pH 
values ranging from 4.0 to 8.0. (26). 
 
Enterococcin Sf3 
E. faecium 3, isolated from human sources, produces a 9 kDa bacteriocin designated 
enterococcin Sf3. Production and immunity is encoded on a 5 kb plasmid. Enterococcin 
Sf3 has a narrow inhibitory spectrum, is thermostable, and is sensitive to proteolytic 
enzymes (21, 33). 
 
Enterocin CRL 50 
The bacteriocin is produced by a E. faecium strain, isolated from Argentinian cheese (66). 
 
Bacteriocin Bc-48 
E. faecalis S-48 and its mutant B-48-28 secretes bacteriocin Bc-48. The bacteriocin is 
highly sensitive to temperature. Partial inactivation occurs during incubation at 45oC for 
60 min., and all activity is lost upon incubation at 50oC for 60 min. However, bacteriocin 
preparations are stable at 4oC for 1 week or at –20oC for 3 months without any loss in 
activity. Bacteriocin Bc-48 is stable in a pH range between 5.5 and 9.0, while a more 
acidic or basic pH causes inactivation. Bacteriocin activity is resistant to lipase, 
lysozyme, DNase, RNase, catalase or alkaline phosphatase. However, the proteolytic 
enzymes trypsin, pronase or protease type XI cause complete inactivation. The inhibitory 
spectrum of bacteriocin Bc-48 is restricted to related strains. Only strains of E. faecalis 
are inhibited. Not all strains are equally sensitive to bacteriocin Bc-48. The bacteriocin is 
produced during logarithmic growth, but production stops once the cultures reaches 
stationary phase. The peptide has a molecular mass of 80 kDa and a pI of 7.0. Bacteriocin 
Bc-48 inhibits protein synthesis, but does not affect amino acid uptake, which suggests 
the contribution of bacteriolysis to cell death. The production and immunity of 
bacteriocin Bc-48 are encoded by a 90 kb plasmid (66). 
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Peptide AS-48 
Another inhibitory agent produced by E. faecalis S-48 is the peptide antibiotic AS-48 
(21, 66). Peptide AS-48 production occurs during exponential growth (68). Production 
and immunity are encoded by a 58 kb plasmid, pMB2 (21, 66). The inhibitor is a 8 kDa 
protein, has a bactericidal effect with a wide inhibitory spectrum including Gram-positive 
and Gram-negative bacteria (21). Unlike most other bacteriocins, this peptide is a cyclic 
molecule arising from a ‘tail-to-head’ linkage that results from post-translational 
modification of the primary product during secretion (32, 68). Peptide AS-48 is 
thermolabile and sensitive to proteolytic enzymes (21). It has a molecular mass of 7.4 
kDa, a basic isoelectric point and a high stability to acid pH (66). The site of action is the 
bacterial membrane, and prolonged exposure leads to cell lysis as a secondary effect, due 
to the activation of autolysins (21). E. faecalis 39-5Sa produces bacteriocin 21 which is 
identical to peptide AS-48. Bacteriocin 21 is encoded on a 59 kb plasmid, pPD1 (48). 
 
Enterococcin EFS2 
E. faecalis EFS2, isolated from cheese, produces enterococcin EFS2 inhibitory towards 
Leuconostoc lactis, L. mesenteroides subsp. dextranicum, L. mesenteroides subsp. 
mesenteroides, L. mesenteroides subsp. paramesenteroides, Listeria ivanovii, L. 
monocytogenes, L. seeligeri, L. welshmeri, L. innocua, C. tyrobutyricum, L. fermentum, 
L. lactis subsp. cremoris, L. lactis subsp. lactis and S. aureus. Enterococcin EFS2 induces 
pore formation in the plasma membrane, efflux of K+ ions and ATP, and cell lysis. 
Maximum bacteriocin activity is found at the beginning of stationary growth. At pH 7.0 
the bacteriocin activity is highest at 35oC and lost at 15oC. The peptide is more active at 
pH 6.0, 7.0 and 8.0 than at pH 4.5 at 30oC (67). Enterococcin EFS2 is a strongly 
hydrophobic molecule consisting of 67 amino acids and a molecular weight of 7149.6 
Da. The bacteriocin has several features identical to peptide AS-48, including molecular 
mass, amino acid composition and cyclic structure which could indicate that enterococcin 
EFS2 might in fact be peptide AS-48 (68). 
 
Enterocin 4 
E. faecalis INIA 4, isolated from raw ewe’s milk and Manchego cheese, also produce a 
cyclic peptide, termed enterocin 4, with bactericidal activity against histamine-producing 
Lactobacillus buchneri, L. brevis, Salmonella cholerasuis, E. faecalis, E. faecium, L. 
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monocytogenes, L. innocua, S. aureus and strains of C. tyrobutyricum. Enterocin 4 is also 
active against Bacillus laterosporus, Enterococcus durans, Corynebacterium 
laevaniformans and energized cells of L. buchneri St2A (49). Enterocin 4 decreased the 
counts of L. monocytogenes Ohio, but was unable to inhibit L. monocytogenes Scott A, at 
least in the pH range 5.2 to 5.4, during the manufacture and ripening of Manchego cheese 
(81). Enterocin 4 displays no activity against Gram-negative bacteria (49). However, it is 
possible that enterocin 4 was not tested at concentrations high enough to inhibit Gram-
negative bacteria. The structural gene encoding enterocin 4 is identical to that encoding 
peptide AS-48, which suggests that enterocin 4 may also be peptide AS-48 (68).  
 
Enterocins 1071A and 1071B 
E. faecalis BFE 1071, isolated from the faeces of minipigs, produces enterocins 1071A 
and 1071B inhibitory towards strains of C. tyrobutyricum and E. faecalis. The 
bacteriocins are also active against Lactobacillus salivarius subsp. salivarius, 
Peptostreptococcus aerogenes, Propionibacterium freudenreichii subsp. shermanii, E. 
durans, L. innocua, Micrococcus sp. DF 132 and S. agalactiae. Enterocins 1071A and 
1071B are resistant to heat of 100oC for 60 min. Approximately 50% of the antibacterial 
activity is retained after 15 min at 121oC. The enterocins are not drastically affected by 
incubation at pH values ranging from 3 to 12, but they are sensitive to α-chymotrypsin, 
papain, pepsin, pronase, proteinase K and trypsin. The genes encoding enterocins 1071A 
and 1071B are located on a 50 kb plasmid (pEF1071) giving rise to 39- and 34 amino 
acid peptides, respectively. Enterocins 1071A and 1071B are 4.825 kDa and 3.899 kDa in 
sizes, respectively (6). 
 
Enterocin EJ97 
E. faecalis EJ97, isolated from municipal waste waters, produces enterocin EJ97 
inhibitory to E. faecalis, E. faecium and Bacillus stearothermophilus, Bacillus circulans, 
Bacillus coagulans, Bacillus megaterium, Bacillus subtilis, Paenibacillus macerans, 
Listeria grayi, L. innocua, L. ivanovii, L. monocytogenes, L. murrayi, L. welshmeri and S. 
aureus. Enterocin EJ97 is produced during exponential growth with maximum activity 
obtained after 7 to 8 h. The bacteriocin retained 100% of its initial activity in a pH range 
from 2.0 to 9.5, and at temperatures between 50 and 80oC, and after being stored for 1 
week at 4oC or for 6 months at –20oC or –70oC. A 30% loss in activity of occurs after 
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heating at 100oC for 30 min. Enterocin EJ97 is totally inactivated by trypsin and pronase 
but is not affected by EDTA or by SDS and Tween 80. No loss of bacteriocin activity is 
recorded after being heated in the presence of DL-dithiothreitol or 2-mercaptoethanol. 
Enterocin EJ97 is an ampiphatic, hydrophobic molecule with a molecular mass of 5.340 
kDa (35). 
 
Enterocin 226NWC 
E. faecalis 226, isolated from natural whey cultures, produces enterocin 226NWC 
inhibitory towards L. monocytogenes, L. innocua, E. faecalis and E. casseliflavus. 
Enterocin 226NWC has a bactericidal effect. The bacteriocin is produced after 6 h during 
mid-logarithmic growth with maximum activity reached after 10 h in late logarithmic to 
early stationary growth. The bacteriocin is stable at 90oC for 30 min, with 50% activity 
remaining after 30 min at 100oC. The peptide is completely inactivated after autoclaving 
(121oC for 15 min) and after treatment with α-chymotrypsin, trypsin, pronase E, papain 
and proteinase K. Treatment with pepsin, lysozyme, catalase, lipase (type VII) and α-
amylase also have no effect on the antibacterial activity of enterocin 226NWC. 
Production of the bacteriocin is encoded by a 5.2 kb conjugative plasmid. The peptide is 
5800 Da in size (113). 
 
Enterocin SE-K4 
E. faecalis K-4, isolated from grass silage, produce enterocin SE-K4 with bactericidal 
activity against Bacillus subtilis, Clostridium beijerinckii, E. faecium, E. faecalis and L. 
monocytogenes. Enterocin SE-K4 is produced during exponential growth. Since E. 
faecalis SE-K4 is a thermophilic Enterococcus, maximal concentrations of the 
bacteriocin is produced at 43 to 45oC. It has a molecular mass of 5362.2 Da. The 
bacteriocin has high heat stability with 50% residual activity obtained after heating at 
100oC for 60 min. More than 25% of its maximal activity is retained between pH 3.0 and 
11.0 (23). 
 
Haemolysin/bacteriocin 
E. faecalis subsp. zymogenes DS16 produces a haemolysin/bacteriocin, which is a two 
component bacteriocin with both haemolytic and bacteriocin activity (32, 48). The 
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bacteriocin is encoded on a 58 kb conjugative plasmid, pAD1 (6). It contains β-
methyllanthionine residues, suggesting that it is a lantibiotic (32, 48). 
 
Streptocin E-1 
E. faecalis E-1, isolated from clinical material (conjunctiva), produces streptocin E-1 
which is particularly active towards Diplococcus pneumoniae. The peptide also inhibits 
non-hemolytic strains of enterococci and strains from the Viridans group of streptococci. 
The bacteriocin is heat labile (80oC, 20 min), chloroform- and trypsin-resistant and has a 
molecular mass of approximately 30 kDa (21). 
 
Bacteriocin 31 
E. faecalis YI717 produces bacteriocin 31 which inhibits E. hirae, E. faecium and L. 
monocytogenes. The bacteriocin is heat stable, is encoded by a 57.5 kb conjugative 
plasmid, pYI17, and contains 43 amino acids. Bacteriocin 31 is similar to enterocin P. It 
is a pediocin-like, class II bacteriocin secreted by the sec-pathway (32, 107). 
 
Mundticin 
Enterococcus mundtii ATO6, isolated from fresh chicory endive, produces mundticin 
which prevents the outgrowth of spores and vegetative cells of toxin-producing strains of 
C. botulinum. Mundticin inhibits the growth of Carnobacterium piscicola, Pediococcus 
dextrinicus, P. pentosaceus, Leuconostoc paramesenteroides, L. mesenteroides, L. 
salivarius, L. sakei, E. faecalis, E. hirae, L. innocua, and Gram-negative bacteria and 
fungi. Mundticin is a class IIa bacteriocin. Proteolytic treatment of the bacteriocin results 
in total loss of the activity. The antimicrobial activity of the peptide is not affected by 
heating for 15 min at 100oC, but prolonged heating for 1 h at 100oC results in a 50% loss 
of activity. The peptide is stable from pH 1 to 10 for 14 h at 4oC. Mundticin is a 
positively charged, hydrophobic, 43 amino acid peptide, with a highly conserved 
YGNGV motif at positions 3-7 with an average mass of 4278.8 Da. It exerts its action on 
the cytoplasmic membrane, which involves the dissipation of the membrane potential and 
a depletion of the intracellular ATP pools. The observed reduction of the ATP pool size 
can be explained by the accelerated consumption of ATP to regenerate the decreased 
PMF and/or by a shift in the ATP hydrolysis equilibrium resulting from phosphate efflux 
(7). 
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Enterocin 012 
Enterococcus gallinarum 012, isolated from the duodenum of ostrich, produces enterocin 
012 which inhibits Lactobacillus acidophilus, L. sakei, Propionibacterium 
acidipropionici, Propionibacterium sp., E. faecalis, L. innocua, C. perfringens, 
Pseudomonas aeruginosa, Salmonella typhimurium and E. coli. The bacteriocin has a 
bactericidal and bacteriolytic mode of action. Enterocin 012 is produced during mid-
logarithmic growth with further increases into stationary growth. No bacteriocin activity 
is lost after heat treatment (30 min at 60oC). A loss of 50% and 75% was recorded after 
30 min at 80oC and 121oC for 15 min, respectively. Incubation at pH 6.0 to 10.0 at 4oC 
did not result in any loss of activity. A loss of 50% activity was recorded when incubated 
at a pH range of 1.0 to 5.0 and at pH 11.0 and 12.0, respectively. Enterocin 012 is 
resistant to treatment with lysozyme, catalase, lipase and papain, but resistant to 
proteinase K, α-chymotrypsin, trypsin and pepsin. The peptide is hydrophobic with a 
molecular mass of 3.4 kDa (48). 
 
 
Bacteriocins produced by Lactobacillus spp. 
 
Lactobacilli are widespread in nature and consist of 64 valid species (21, 100). They are 
present in a variety of habitats, such as mucosal membranes of man and animal, e.g. the 
oral cavity, intestines and vagina (118). Animals such as pigs, chickens, dogs, mice, rats 
and hamsters harbour predominantly Lactobacillus flora in their intestines (117). They 
are also found on plants or material of plant origin, in manure and man-made habitats 
such as sewage and fermenting or spoiled food (118). Bacteriocin-producing 
Lactobacillus spp. are present in many foods, including salads and cheese as well as dry 
and fermented sausages. Most of the characterized bacteriocins from Lactobacillus are 
classified as Class I or II (21). A number of them are inhibitory to Listeria spp. (111). 
 
L. plantarum BF001, isolated from spoiled cattle fish, produces plantaracin F which 
inhibits several strains of LAB and foodborne pathogens such as Pseudomonas 
aeroginosa, L. monocytogenes, S. aureus, and salmonellas (34, 87). 
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L. plantarum strains Lb 75 and Lb 592, isolated from fresh meat and different meat 
products, inhibits Lactobacillus divergens, L. sakei, L. curvatus , L. monocytogenes but 
not L. plantarum (102). 
 
L. plantarum strains CTC 242, CTC 244, CTC 272, CTC 305, CTC 306, CTC 316 
produce antagonistic activity. L. plantarum ATCC 8014 is inhibited by compounds 
produced by strains CTC 242, CTC 244, CTC 305, CTC 316. L. plantarum DSM 20174 
is inhibited by all six strains. A laboratory strain of L. curvatus is inhibited by strains 
CTC 242, CTC 244, CTC 306 while L. sakei is inhibited by strains CTC 242, CTC 244 
and CTC 272 (36). Strains CTC 305 and CTC 306 inhibit L. monocytogenes and a 
laboratory strain of E. faecalis (102). Both peptides have a bactericidal action against L. 
monocytogenes (110). 
 
Plantaracin EF and JK 
L. plantarum C-11, isolated from a natural cucumber fermentation, produces two two-
peptide bacteriocins termed plantaracin EF and JK. Both peptides are Class II 
bacteriocins (21). 
 
Plantacin B 
Plantacin B is produced by L. plantarum NCFB 1193 and inhibits Pediococcus 
damnosus, L. plantarum, L. mesenteroides, L. mesenteroides subsp. mesenteroides and 
(21). The peptide is also produced by L. plantarum NCDO 1193 (111). 
 
Plantaracin S and T 
L. plantarum LPCO-10, isolated from a green olive fermentation, produces plantaracin S 
and T. Plantaracin S inhibits E. faecalis, C. tyrobutyricum and several Lactobacillus, 
Lactococcus, Leuconostoc, Pediococcus, Streptococcus, Micrococcus, and 
Propionibacterium spp. Plantaracin T exhibits a lower level of inhibition against the 
various organisms tested for plantaracin S (111). 
 
Plantaracin 423 
The bacteriocin is produced by L. plantarum 423 isolated from sorghum beer and is 
inhibitory to several food spoilage bacteria and food-borne pathogens, including 
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Staphylococcus carnosus, B. cereus, C. sporogenes, E. faecalis, several Lactobacillus sp., 
(including L. plantarum), Propionibacterium acidipropionici, Propionibacterium sp., 
Oenococcus oeni, L. innocua, L. monocytogenes, P. acidilactici, P. pentosaceus and S. 
thermophilus. Plantaracin 423 has a bactericidal mode of action and is a class IIa (anti-
Listeria) bacteriocin (111). 
 
Plantaracin ST31 
The bacteriocin is produced by L. plantarum ST31 isolated from sourdough. The 
bacteriocin inhibits strains of the genera Lactobacillus, Leuconostoc, Pediococcus, 
Streptococcus, Bacillus and certain foodborne pathogens such as S. aureus (106). 
 
Plantaracin C19 
The bacteriocin is produced by L. plantarum C19 isolated from fermented cucumbers. It 
is inhibitory towards several Gram-positive pathogenic and spoilage bacteria, but the 
activity is weak or nonexistent. Plantaracin C19 is a class II bacteriocin (4). 
 
Plantaracin C 
This peptide, classified as a lantibiotic, is produced by L. plantarum LL441, isolated from 
Cabrales cheese, and is inhibitory towards several strains of lactobacilli, leuconostocs, 
pediococci and S. thermophilus (38). 
 
Plantaracin UG1 
The bacteriocin is produced by L. plantarum UG1 isolated from dry sausage. The peptide 
inhibits several strains of lactobacilli and lactococci, and certain foodborne pathogens, 
such as B. cereus, L. monocytogenes, C. perfringens and C. sporogenes (25). 
 
Plantacin 154 
The bacteriocin is produced by L. plantarum LTF 154 isolated from fermented sausage. It 
inhibits E. faecalis, various Lactobacillus sp. such as L. acidophilus, L. casei, L. 
fermentum and L. plantarum, P. acidilactici and P. pentosaceus, S. lactis and S. 
thermophilus, Propionibacterium jensenni, Propionibacterium theonnii and P. 
acidipropionici (52). 
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Plantaracin KW30 
The bacteriocin is produced by L. plantarum KW30, isolated from fermented corn. Its 
inhibition spectrum is restricted to L. brevis, L. delbrueckii subsp. lactis and L. plantarum 
strains (53). 
 
Plantaracin-149 
The bacteriocin is produced by L. plantarum NRIC 149 isolated from pineapple. The 
peptide inhibits strains of Pediococcus cerevisae, P. acidilactici, L. plantarum, L. 
delbrueckii, L. helveticus, L. casei, L. fermentum, L. mesenteroides, E. hirae and L. lactis 
(50). 
 
Plantaracin LC74 
Plantaracin LC74 is produced by L. plantarum LC74 isolated from crude goat’s milk. It 
inhibits strains of Bacillus stearothermophilus, L. plantarum, L. brevis, L. buchneri and 
L. mesenteroides (91). 
 
Plantaracin SA6 
The bacteriocin is produced by L. plantarum SA6 isolated from fermented sausage. The 
peptide inxhibits several LAB including L. plantarum, L. brevis, L. buchneri, L. 
paramesenteroides and Listeria grayi (92). 
 
Plantaracin D 
The bacteriocin is produced by L. plantarum BFE 905 isolated from “Waldorf” salad. 
The peptide has a narrow spectrum of inhibition, being antagonistic against only one 
strain of L. plantarum, one strain of L. sakei and several L. monocytogenes strains (31). 
 
Plantaracin BN 
L. plantarum BN produces plantaracin BN inhibitory towards C. botulinum (83). 
 
Plantaracin NA 
An isolate of L. plantarum sp. from vegetable origin produces plantaracin NA which 
inhibits L. monocytogenes (84). 
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Plantaracin K 
The bacteriocin is produced by L. plantarum DK9 isolated from “fufu”, a fermented 
cassava product. It inhibits strains of Lactobacillus, Leuconostoc and Enterobacter (83). 
 
Other bacteriocins produced by L. plantarum include plantaracin A, plantaracin F, 
plantaracin 154, plantaracin 406, and produced by L. plantarum strains BN, LB75, 
LB592, CTC305, respectively (12). L. plantarum TMW 1.25 produces plantaracin 1.25α 
and plantaracinβ (93). 
 
Lactocin S 
L. sakei L45, isolated from fermented dry sausage, produces lactocin S. The bacteriocin 
is active only towards selected species of the genera Lactobacillus, Leuconostoc and 
Pediococcus (46, 54). Lactocin S is a lantibiotic (21).  
 
Sakacin P 
L. sakei LTH673 produces sakacin P, which is active towards closely related lactobacilli, 
Carnobacterium spp., E. faecalis and Listeria spp (21). 
 
Sakacin 674 
The bacteriocin is produced by L. sakei Lb674. The peptide inhibits the growth of several 
Lactobacillus spp. and L. monocytogenes. Subsequent studies have shown that sakacins P 
and 674 are identical. It is a class IIa bacteriocin (21). 
 
Sakacin A 
L. sakei Lb 706, isolated from different types of meat and meat products, produces 
sakacin A which is active against L. monocytogenes, L. ivanovii, L. innocua and a variety 
of LAB, including lactobacilli, enterococci and carnobacteria. An inhibition of 
Aeromonas hydrophila has also been observed. The bacteriocin has a bactericidal mode 
of action (21). 
 
Bavaracin MN 
The bacteriocin is produced by L. sakei MN. Bavaracin MN is a Class IIa bacteriocin 
(21). 
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L. sakei CTC 472 produces a bacteriocin, which inhibits Listeria spp. Many L. sakei 
strains isolated from meat produce antimicrobial substances while strain Lb 706 inhibits 
L. monocytogenes (21). 
 
Lactacin B 
L. acidophilus N2 produces lactacin B inhibitory towards L. delbrueckii subsp. lactis, L. 
delbrueckii subsp. lactis ATCC 4797, L. delbrueckii subsp. lactis NCDO 970, L. 
delbrueckii subsp. bulgaricus NCDO 1489, L. acidophilus ATCC 6032 and L. helveticus 
NCDO 87. The production of lactacin B appears to be genomically encoded (21). 
 
Acidophilucin A 
L. acidophilus LAPT 1060, isolated from infant faeces, produces acidophilucin A 
inhibitory towards L. delbrueckii subsp. bulgaricus and L. helveticus. Acidophilucin A is 
a Class III bacteriocin (21). 
 
Acidocin A 
Acidocin A, produced by L. acidophilus TK9201, a starter organism for fermented milk, 
is inhibitory towards several closely related LAB and L. monocytogenes (21). 
 
Acidocin B 
This bacteriocin is plasmid-encoded and produced by L. acidophilus M46. The peptide is 
inhibitory towards Brochothrix thermosphacta L. monocytogenes, C. sporogenes, L. 
fermentum and L. delbrueckii subsp. bulgaricus, but inactive against most other 
Lactobacillus spp (21). 
 
L. acidophilus JCM 1132 produces the two-peptide bacteriocin, acidocin J1132. Acidocin 
8912 is produced by L. acidophilus TK9812 (21). 
 
Curvacin A 
Curvacin A was the first bacteriocin identified and characterized from a strain of L. 
curvatus (LTH 1174), isolated from fermented sausage. It has a bactericidal mode of 
action, including cell lysis, and is effective against closely related lactobacilli as well as 
organisms causing food spoilage of meat, including E. faecalis, Carnobacterium spp., 
 62
and Listeria spp. The growth of micrococci and strains of S. carnosus, which are 
constituents of meat starter preparations, was not affected (21). Later studies showed that 
the bacteriocin is identical to sakacin A (110). 
 
Other bacteriocins produced by L. curvatus include curvaticin FS47 produced by strain 
FS47, isolated from meat, and curvaticin 13, produced by strain SB13 (37, 104). 
 
Lactocin 27 
Lactocin 27 is produced by the homofermentative L. helveticus LP27, and shows a 
narrow spectrum of activity limited to L. acidophilus and L. helveticus. It imparts its 
bacteriostatic effects by inhibiting protein synthesis and by interfering with sodium and 
potassium transport (21, 100). 
 
Helveticin J 
The bacteriocin is produced by L. helveticus NCDO 481 and shows a narrow inhibitory 
spectrum which includes strains of L. helveticus, L. delbrueckii subsp. bulgaricus and L. 
delbrueckii subsp. lactis. Helveticin J is a Class III bacteriocin. It has a bactericidal mode 
of action and its genetic determinants are chromosomally localized. Helveticin V-1829 is 
produced by L. helveticus V-1289 (21). 
 
Lactacin F 
Lactobacillus johnsonni VPI11088 produces lactacin F. The bacteriocin is a hydrophobic, 
heat-stable peptide belonging to the Class II bacteriocins. It is inhibitory towards L. 
delbrueckii subsp. lactis, L. delbrueckii subsp. bulgaricus, L. acidophilus, L. helveticus, 
L. fermentum, E. faecalis, S. aureus and Aeromonas hydrophila (21, 64). 
 
Caseicin 80 
L. casei B 80, isolated from wine, produces caseicin 80 that is active only towards 
another strain of L. casei (B 109) (90). Another caseicin-producing L. casei strain (LHS) 
with a wide spectrum of activity was also isolated from sherry (19). Caseicin is a class III 
bacteriocin (21). 
 
L. casei CRL 705, isolated from dry sausages, produces lactacin 705 (112). 
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Lactacin A 
L. delbrueckii subsp. lactis JCM 1106 and JCM 1107 produce lacticin A which is active 
towards L. delbrueckii subsp. bulgaricus, L. delbrueckii subsp. lactis and L. delbrueckii 
subsp. delbrueckii. The peptide is a Class II bacteriocin (21). 
 
Lactacin B 
L. delbrueckii subsp. lactis JCM 1248 produces lacticin B which is active only towards L. 
delbrueckii subsp. bulgaricus NIAI yB-62. The peptide is a Class II bacteriocin (21). 
 
Brevecin 27 
The bacteriocin is produced by L. brevis SB27 and mainly inhibits strains of closely 
related L. brevis and L. buchneri (8). 
 
Brevecin 286 is produced by L. brevis VB286 isolated from vacuum-packaged meat (16). 
Brevicin is produced by L. brevis 37 (90). 
 
Reutericin 6 
Lactobacillus reuteri LA 6, isolated from infant faeces, produces reutericin 6 which is 
inhibitory towards L. acidophilus, L. delbrueckii subsp. bulgaricus and L. delbrueckii 
subsp. lactis. Reutericin is another bacteriocin produced by L. reuteri LA6 (21). 
 
Bacteriocins from L. salivarius are salavaricin A produced by L. salivarius 20P3, 
salavaricin B produced by strain M7 and salavacin 140 produced by L. salivarius subsp. 
salicinius T140 (3, 97, 105). 
 
Bacteriocins produced by Lactobacillus amylovirus include lactobin A, produced by 
strain LMG P-13139 isolated from corn steep liquor, and amylovirin L471 produced by 
strain DCE471 (9, 15). 
 
Pentocin D 
Lactobacillus pentosus DK7 isolated from “ogi”, a fermented maize product, produce 
pentocin D which inhibits strains of Lactobacillus, Leuconostoc and Enterobacter sp. 
(86). 
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Bavaracin A 
The bacteriocin is produced by Lactobacillus bavaricus MI401. Bavaracin A has a 
bactericidal mode of action against several L. monocytogenes strains (56). 
 
L. fermentum 466 produces bacteriocin 466. Fermenticin is another bacteriocin produced 
by this species (21). 
 
Brevecin 37 
L. brevis produces brevicin 37 which is active against many other LAB and Nocardia 
corallina (21). 
 
Gassericin A is produced by Lactobacillus gasseri LA39 (51). 
 
 
Bacteriocins produced by Lactococcus spp. 
 
The ability of some lactococci to produce inhibitory substances other than organic acids 
has been known for quite some time. The genus Lactococcus includes Lactococcus 
garviae, Lactococcus plantarum, Lactococcus raffinolactis, L. lactis subsp. lactis, L. 
lactis subsp. cremoris, L. lactis subsp. hordniae (21). Most lactococci occur in the dairy 
industry although other sources do exist for different species (118). The Lactococcus 
genus has been known to produce two types of bacteriocins: the first type only affects 
closely related species whereas the second one is effective against many Gram-positive 
genera (77). 
 
Nisin 
This polypeptide is produced by L. lactis subsp. lactis (21, 100). Nisin-producing 
lactococci have been isolated from raw and pasteurized milk and cheese, human and 
bovine faeces as well as the human throat. Other sources where nisin-producing 
lactococci have been isolated include fermented carrots and also a commercial sauerkraut 
tank. The active protein consists of 34 amino acids and has a molecular mass of 3500 Da. 
It can exist in multimeric forms. Nisin contains four unusual amino acids, namely 
dehydroalanine, dehydrobutyrine, lanthionine and β-methyl lanthionine. Because of the 
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presence of these unusual amino acids, nisin is classified as a lantibiotic. Nisin is 
ribosomally synthesized as a prepeptide and postranslationally converted into a mature 
peptide (109). Nisin displays a rather broad inhibitory spectrum. It inhibits the majority 
of Gram-positive bacteria of which the lactococci are especially sensitive. It further 
inhibits several strains of bacilli, clostridia, corynebacteria, lactobacilli, leuconostocs, 
micrococci, pediococci, pneumococci, streptococci and actinomycetes. Staphylococcus 
pyogenes, Staphylococcus epidermidis, S. aureus, Mycobacterium tuberculosis, 
Erysipelothrix rhusiopathiae and L. monocytogenes are also sensitive to nisin. Nisin has a 
bactericidal mode of action and is effective not only against the vegetative cells of spore-
forming bacilli and clostridia, but even more against their spores (21). In spores, the 
cytoplasmic membrane is apparently destroyed immediately after germination (100). 
Nisin Z, produced by L. lactis subsp. lactis strain NIZO 22186 is a natural variant of nisin 
A (78). 
 
Lacticin 481 
The bacteriocin is produced by L. lactis subsp. lactis CNRZ 481. It is active against 
lactobacilli, especially L. delbrueckii subsp. bulgaricus, L. helveticus, some leuconostocs, 
pediococci and S. thermophilus. In food spoilage, lacticin 481 is active only against C. 
tyrobutyricum and S. carnosus. It has a bactericidal mode of action and acts similarly to 
nisin by forming ion channels in the membrane of sensitive cells. The lantibiotic 
lactococcin DR, produced by L. lactis subsp. lactis ADRIA 85LO30 is identical to 
lacticin 481 (21). 
 
Lacticin 3147 
Lacticin 3147 is a broad-spectrum bacteriocin produced by L. lactis DPC3147, isolated 
from Irish kefir grains. The peptide is heat stable, particularly at low pH, and is produced 
during logarithmic growth but is however not related to nisin (98). It is inhibitory to a 
wide range of Gram-positive organisms, including strains of Listeria, clostridia, 
Enterococcus, Staphylococcus and Streptococcus (76). Lacticin 3147 is more effective 
against streptococci than staphylococci when compared to nisin (99). Streptococcus 
dysgalactiae M is the most sensitive (98). 
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Lactococcins 
Lactococcins R9/1, R9/2, R10/1 and R35 are produced by L. lactis subsp. lactis strains 
R9/1, R9/2, R10/1 and R35, respectively. These lactococcins displays a broad inhibitory 
spectrum of activity against Carnobacterium piscicola, S. aureus, L. lactis subsp. lactis 
and Listeria strains. Lactococcin R9/2 and R10/1 show the broadest range of inhibitory 
action (23). 
 
L. lactis subsp. cremoris 9B4 produces lactococcin A, B and M while lactococcin A is 
produced by strain LMG 2130 (21). The antagonistic activity of strain 9B4 affects the 
growth of lactococci and some Clostridium species. Lactococcin A only inhibits the 
growth of lactococci. The action of lactococcin A on sensitive cells is bactericidal. 
Lactococcin A and B are also produced by L. lactis subsp. lactis biovar. diacetylactis 
WM4 (21). 
 
Lactococcin G, produced by L. lactis LMG 2081, is a two-peptide bacteriocin that 
inhibits various LAB and different clostridia (80). 
 
L. lactis subsp. lactis IPLA 972, isolated from homemade cheese, produces lactococcin 
972 (70). 
 
Diplococcin 
Diplococcin is produced by L. lactis subsp. cremoris. The inhibitory spectrum of 
diplococcin is restricted to other L. lactis subsp. cremoris and lactis strains (20). 
 
Lactostrepcins 
This is another class of bacteriocins produced by other genera of lactococci, i.e. L. lactis 
subsp. lactis, L. lactis subsp. lactis var. diacetylactis and L. lactis subsp. cremoris.. These 
antimicrobial proteins are unique in that they are active only in the acid pH range. Five 
types of lactostrepcins can be defined. Lactostrepcin (Las 5) is effective against L. lactis 
subsp. lactis, L. lactis subsp. cremoris and L. lactis subsp. lactis var. diacetylactis. 
Besides activity against various lactococci, Las 5 is also active against strains of 
Leuconostoc, L. helveticus and B. cereus. Las 1 displays high activity against group A, C 
and G streptococcal and against L. helveticus strains. The same strains together with 
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Leuconostoc strains are highly susceptible to Las 2. Las 3 is effective only against L. 
lactis subsp. cremoris 1P5 while Las 4 is active against both L. lactis subsp lactis and L. 
lactis subsp. cremoris. Lactostrepcins exert a strong and rapid bactericidal on sensitive 
cells during exponential growth (21). 
 
 
Bacteriocins produced by Carnobacterium spp. 
 
The genus Carnobacterium accommodates some physiologically, biochemically and 
chemically atypical lactobacilli (21), isolated from: meat and meat products, poultry, fish 
and seawater (118). The genus at present includes Carnobacterium divergens, 
Carnobacterium gallinarum, Carnobacterium mobile and C. piscicola (21). 
 
All bacteriocin-producing strains of carnobacteria are identified as C. piscicola and were 
isolated from meat or fish although bacteriocinogenic strains of C. divergens have been 
reported more recently. The bacteriocins produced by C. piscicola are mostly small 
hydrophobic peptides. Their antibacterial spectrum comprises different genera of LAB 
and generally includes L. monocytogenes (118). 
 
Carnobacteriocin A and B 
C. piscicola LV17, isolated from vacuum-packaged meat, produces three bacteriocins, nl. 
carnobacteriocin (Cbn) A, B and BM1. In contrast to Cbn A and B, which is encoded by 
a plasmid, Cbn BM1 is chromosomally encoded. However, the transport genes for Cbn 
BM1 are encoded in trans by the transport genes of Cbn B. The bacteriocins are active 
against other LAB (carnobacteria, lactobacilli, pediococci) and strains of Enterococcus 
and Listeria spp. The bacteriocins have a bactericidal mode of action (21, 118). 
 
Pisicolin 61  
C. piscicola LV61 produces pisicolin 61 which is active against other Carnobacterium, 
Lactobacillus, Leuconostoc, Pediococcus, Enterococcus and L. monocytogenes (21, 118). 
Other LAB such as lactobacilli, pediococci and leuconostocs were more or less resistant 
(21). 
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Carnocin UI49 
C. piscicola UI49, isolated from fish, produces carnocin UI49 which is active against a 
wide range of LAB. It has a bactericdal mode of action and is classified as a lantibiotic 
(21). 
 
Piscicocin V1a and V1b 
C. piscicola V1, isolated from fish, produces piscicocin V1a and piscicocin V1b which 
inhibit various Gram-positive bacteria, including L. monocytogenes (21, 118). 
 
Piscicolin 126 
The bacteriocin is produced by a C. pissicola strain isolated from spoiled ham and 
inhibits several species of Enterococcus, Lactobacillus, Leuconostoc, Listeria and S. 
thermophilus (21, 118).  
 
Carnocin CP51 and CP52 
C. piscicola CP5, isolated from French mold-ripened cheese, produce two anti-listerial 
bacteriocins, carnocin CP51 and CP52 (21, 118). 
C. piscicola UAL26 produces a chromosomally mediated bacteriocin of which the 
activity spectrum extends beyond very closely related species, which include 
Enterococcus and Listeria spp. C. piscicola strains DX and GN, isolated from beef, 
produce bacteriocins that are active against L. monocytogenes and A. hydrophila (21, 
118). 
 
Divergicin 750 
The bacteriocin produced by C. divergens, inhibits species of Carnobacterium, 
Enterococcus and Listeria, as well as C. perfringens (46). 
 
Other bacteriocins produced by C. divergens include divergicin A produced by strain 
LV13 isolated from meat and divergicin V41 produced by strain V41 isolated from fish 
viscera (71, 89, 119). 
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Bacteriocins produced by Leuconostoc and Weisella spp. 
 
The genus Leuconostoc comprises Gram-positive cocci that are claimed to be 
taxonomically and ecologically related to group N streptococci. However, leuconostocs 
are heterofermentative and produce rod-shaped cells in growth media, making them 
similar to heterofermentative lactobacilli (103). The genus currently comprises 10 
species. Leuconostocs are found on plants, milk and dairy products, fermented food 
products and have been isolated from the lactic microflora of chill-stored vacuum-
packaged meats (21, 118). Inhibition by Leuconostoc has been attributed primarily to 
production of lactic and acetic acid as well as diacetyl. However, there have been reports 
of bacteriocin-like compounds produced by the genus (100). Most of these compounds 
are small, heat stable peptides classified as Class IIa bacteriocins although several 
characterized bacteriocins in this genus cannot be classified in the currently described 
groups (25, 60). Bacteriocins produced by leuconostocs may or may not be active against 
other LAB, but all include Listeria in their activity spectra (103). 
 
Leucocin A-UAL 187 
Leuconostoc gelidum, isolated from chill-stored vacuum packaged meat, produces 
leucocin A-UAL 187. Leucocin A is classified as a Class IIa bacteriocin. The 
antibacterial spectrum of the bacteriocin includes other LAB, L. monocytogenes and E. 
faecalis; however the activity may be bacteriostatic rather than bactericidal (42). 
 
Carnosin 44A 
Leuconostoc carnosum, isolated from Vienna-type sausages, produces carnosin 44A (21, 
103). It has a similar antibacterial spectrum to leucocin A, including Enterococcus and 
Listeria spp (21). 
 
Leucocin B-Ta11a 
L. carnosum Ta11a, isolated from vacuum packaged vienna sausages, produces leucocin 
B-Ta11a. Leucocin B is active against L. monocytogenes (21). 
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Leucocin D-La54a 
The bacteriocin is produced by L. carnosum La54a isolated from spoiled vacuum-
packaged vienna sausages. The characteristics of this bacteriocin are similar to leucocin 
A and B (21). 
 
Mesentericin Y105 
L. mesenteroides subsp. mesenteroides, isolated from goat’s milk, produces mesentericin 
Y105 (21). Mesentericin Y105 is classified as a Class IIa bacteriocin (43). Another 
producing strain has also been isolated from cheddar cheese (25). The peptide is 
bactericidal to a wide range of Listeria spp., but not to a limited range of other bacteria, 
including strains of LAB (110). 
 
Other bacteriocins produced by L. mesenteroides include mesenterecin 52A and B 
produced by L. mesenteroides subsp. mesenteroides FR52 and dextranicin 24, produced 
by L. mesenteroides subsp. dextranicum J24 (94, 95). 
 
Leuconocin S 
L. paramesenteroides produces leuconocin S. The bacteriocin is bacteriostatic and it has a 
broad antibacterial spectrum, including strains of Yersinia enterocolitica, C. botulinum, 
L. monocytogenes and S. aureus (21, 103). 
 
L. gelidum, isolated from meat, produces a bacteriocin which inhibits lactobacilli, 
leuconostocs and L. monocytogenes (21, 118). L. mesenteroides produces a bacteriocin 
that has a bacteriostatic effect on strains of Listeria, Brevibacterium linens, E. faecalis 
and P. pentosaceus (118). Production of the bacteriocin is encoded by one of the two 
plasmids present in the organism (110). 
 
Leuconocin J is produced by Leuconostoc sp. J2, isolated from Korean Kimchi. Leucocin 
H is a two-peptide bacteriocin produced by Leuconostoc MF215B. Leucocin F10 is 
produced by L. carnosum strain F10 isolated from meat. Leuconocin S and leucocin C-
LA7a are produced by Weissella paramesenteroides (41, 65). 
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Bacteriocins produced by Pediococcus spp. 
 
The genus is heterogeneous and includes organisms able to grow in beer and those active 
during soya sauce manufacture. They are also found in wine and ciders, soft drinks, 
cheese as well as meat and fish products, etc. (118). 
 
Pediocin A 
P. pentosaceus strains FBB-61 and L-7230, isolated from fermenting cucumber brine, 
produce pediocin A (21). The bacteriocin is also produced by P. pentosaceus FBB-63 
(100). The bacteriocin inhibits the growth of selected strains of Gram-positive bacteria 
from the genera Pediococcus, Lactobacillus, Lactococcus, Leuconostoc, Enterococcus, 
Micrococcus, Clostridium, Staphylococcus and Bacillus (21, 100). 
 
Pediocin AcH 
P. acidilactici H, isolated from fermented sausage, produces pediocin AcH which is 
active against a variety of LAB and strains of Listeria (21, 100). Pediocin AcH binds to 
specific receptors on cell walls of sensitive strains and destabilizes membrane function, 
causing cell death (100). Other pediocin AcH-producing strains include strains H, E, F 
and M of P. acidilactici (21). 
 
Pediocin PA-1 
The bacteriocin is produced by P. acidilactici PAC 1.0. The bacteriocin inhibits other 
pediococci, some lactobacilli, strains of L. mesenteroides subsp. dextranicum and L. 
monocytogenes (100). The bacteriocin is also produced by two Pediococcus parvulus 
strains isolated from minimally processed vegetables (110). 
 
Another bacteriocin produced by P. acidilactici is pediocin SJ-1 (110). Pediocin 5 and 
pediocin PD-1 is produced by P. acidlactici UL5 and P. damnosus NCFB 1832, 
respectively (39, 47). Pediocin production is often plasmid linked (118). Bacteriocins are 
also produced by P. pentosaceus strains MC-01 and MC-03 isolated from pepperoni as 
well as P. acidilactici strains PO2, B5627, PC and HP and some isolated from human 
clinical sources (21). 
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Bacteriocins produced by Streptococcus spp. 
 
Streptococci comprise a significant component of the commensal flora of man and 
animals, colonizing mucous membranes of the mouth, respiratory tract, alimentary tract 
and genitourinary tract. Some species are also found on the skin, and others may be 
isolated from milk and dairy products. Many of the known species are parasitic in man or 
other animals and some are important pathogens (118). The species in the genus can 
roughly be divided into the oral or viridans streptococci and the pyogenic streptococci. 
Pyogenic streptococci are of considerable medical importance. Although oral streptococci 
form an important component of the microflora of the mouth and the upper respiratory 
tracts of humans, they may be isolated from almost any type of clinical specimen, 
including blood cultures, pus, body fluids, biopsies, wounds, etc. or even from soil. Oral 
streptococci comprise at least three groups of species: the mutans group with seven 
species; the oralis group with at least nine species, and the salivarius group (21). 
 
Bacteriocins STB 40 and STB 78 
The bacteriocins are produced by strains of S. thermophilus isolated from milk. The 
bacteriocins are active to other S. thermophilus and Enterococcus strains (21). 
 
Bacteriocin St10 
Bacteriocin St10 is produced by S. thermophilus St10. It is only active towards S. 
thermophilus strains (21). 
 
Other bacteriocins produced by S. thermophilus include thermophilin 13 produced by S. 
thermophilus Sfi13, thermophilin 347, produced by strain 347 isolated from yoghurt, and 
thermophilin T produced by strain ACA-DC0040, isolated from “feta” cheese (1, 69, 
114). 
 
Mutacins 
This is another group of bacteriocins produced by Streptococcus. These peptides have 
bactericidal activity towards Gram-positive bacteria, but not Gram-negative bacteria 
except for Neisseria sicca (117). 
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PROBIOTIC TREATMENT OF MASTITIS 
 
There has been speculation that the administration of probiotic therapy to infected 
mammary glands may be an effective treatment of clinical mastitis. It would be 
economically advantageous if an effective probiotic were to be identified, since this 
would not require any unnecessary withdrawal of milk following treatment. Treatment of 
subclinical mastitis was attempted using intramammary infusions of Lactobacillus spp. 
However, cattle receiving intramammary antibiotic agents had a greater reduction 
(73.7%) than cows infused with Lactobacillus spp. (21.7%). Cows treated with 
intramammary Lactobacillus also had higher somatic cell counts following treatment (40, 
108). 
 
In another study, where elimination of clinical mastitis was attempted, the cure rate for 
Lactobacillus was half that of cephapirin treatment (26% vs. 49%). None of the Gram-
negative bacilli quarters treated with Lactobacillus recovered, while the majority of 
cephapirin-treated quarters were cured. Mean quarter SCC remained unchanged 
following the treatment with Lactobacillus, while it decreased with cephapirin treatment. 
These results do not support the speculation that this type of Lactobacillus product is 
effective in the treatment of clinical mastitis (108). 
 
 
MASTITIS TREATMENT THROUGH BACTERIOCINS 
 
The application of biotechnology to mastitis treatment is opening up new avenues of 
prevention and control. For mastitis treatment, bacteriocins can be either infused into the 
udder (in the same way as antibiotics), or used in solutions (such as teat dips). These 
proteins are larger molecules than antibiotics and are expected to persist in the udder 
longer. Unlike antibiotics, the rapid action of bacteriocins reduces the likelihood of an 
induced resistance in target and nontarget organisms (72). 
 
Current research conducted so far seems to indicate that bacteriocins used for mastitis 
treatment are nontoxic to other organisms. This facilitates their inclusion into food 
products under FDA health regulations. This means that treated lactating or dry cows that 
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calve prematurely need not have their milk withheld, as would be the case with 
antibiotics in subclinical treatment. Although most work to date has been done on 
enzymatic proteins to control S. aureus, research with bactericidal proteins against other 
organisms like S. agalactiae suggests that the conclusions drawn can be generalized (72). 
 
Nisin 
Nisin has been used as a food presevative in certain countries since 1954 and has recently 
gained approval in the United States of America for use in certain dairy products. Nisin is 
nontoxic to humans and is readily broken down by digestive enzymes when consumed. 
Hypersensitivity to nisin has not been recorded. However, it has a low solubility in body 
fluids and is unstable at physiological pH (72, 109). 
 
A purified preparation of nisin has been developed as a suitable sanitizer against mastitis 
pathogens on cows’ teats. This product was able to kill S. aureus and E. coli after a 1-min 
exposure at a rate comparable to one percent iodophor (100). Nisin in combination with 
lysostaphin has also been shown to be an effective treatment for mastitis, with cure rates 
of 66, 95 and 100% reported for animals infected with S. aureus, S. agalactiae and 
Streptococcus uberis respectively. In addition, nisin is now the active ingredient in at 
least two products currently sold for the prevention of mastitis: Consept (Applied 
Microbiology, Inc., New York, N.Y.), which is applied as a teat dip, and Wipe-Out 
(Applied Microbiology), which is used as a teat wipe (98). 
 
Lacticin 3147 
Lacticin 3147 has also been evaluated as a possible means of mastitis control. This 
specific application involved the incorporation of the bacteriocin into a commercial teat 
seal. The teat seal is an oil-based formulation that forms a physical barrier against 
infection in the area of the teat canal and sinus. It consists of a heavy inorganic salt in a 
paraffin base and is antibiotic-free. The effect of this lacticin 3147-containing teat seal is 
two–fold; first, the seal itself provides an effective physical barrier against infection at the 
teat orifice, and secondly, the bacteriocin inhibits any infectious Gram-positive bacteria 
which have the potential to evade the teat seal plug. Its use is preceded by an antibiotic 
treatment at the drying-off stage, and the seal is then administered as an added barrier 
treatment over the antimicrobial protection afforded by the antibiotic. The incorporation 
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of bacteriocin into the teat seal is advantageous in that the bacteriocin is localized within 
the teat seal, which is in the teat duct and sinus (98). 
 
In one study lacticin 3147 appeared to be more potent against streptococci than 
staphylococci. Lacticin 3147 caused rapid cell death when added to actively growing 
cells of S. aureus 10 and S. dysgalactiae M. The addition of lacticin 3147 to 
approximately 106 and 107 of actively growing cells of these organisms caused a rapid 
loss of viability in comparison to control cultures to which no bacteriocin was added. For 
both S. aureus 10 and S. dysgalactiae M, >99.9% of cells were killed within 2 hours 
(using 1,280 and 10,240 AU/ml, respectively), demonstrating the potency of this 
bacteriocin against mastitic pathogens (98). 
 
By using higher concentrations of lacticin 3147, an increased rate of killing was 
observed, indicating that the residual populations were not resistant. The frequency of 
spontaneous resistance was less than 1 in 1 million cells after 24 hours of incubation for 
S. dysgalactiae M, while no resistance was observed after 24 hours of incubation for S. 
aureus 10 (98). 
 
In addition, the somatic cell counts (SCC) were monitored during the morning and 
evening milkings to ensure that the bacteriocin-containing teat seal was non-irritating. No 
notable increase in SCC over that of the untreated controls was observed, suggesting that 
this product is a non-irritating agent. Hence, the teat seal appears to provide a safe and 
effective vehicle for localization of the bacteriocin in the teat canal. Moreover, the 
resultant seal retained its bacteriocin activity even after being infused in the teat of an 
animal (98). 
 
Future prospects 
 
Bacteriocins are comparable with antibiotic treatment and is twice as effective as 
penicillin for first time infections in heifers (72). Combining bacteriocins that produce a 
synergistic action may prove to be very significant. Treating cows with one of these 
combined products is likely to be more effective. Combinations appear to require lower 
concentrations, which may reduce expenses involved in treatment (72). The milk 
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exclusion for such a product would require shortened withholding periods of as little as 1 
day compared with 6.6 days for antibiotic treatments. Milk would only need to be 
withheld because of abnormal secretion but not because of toxicity (72). 
 
The specificity of bacteriocins means that specific bacteriocins will have to be prescribed 
by veterinarians, who are able to determine the organism causing the infection. This is in 
contrast to broad-spectrum antibiotics, which require no prescription for use to control 
mastitis. The cost of a veterinary diagnosis could make enzyme use not cost effective 
compared with antibiotics. However, a combination of several bacteriocins into a single 
medication could allow the products to be sold as non-prescription drugs. Farmers must 
perceive this treatment method as economically competitive with antibiotic alternatives. 
The adoption of enzymes is expected to be slow initially, until the treatment can be sold 
as a non-prescriptive drug (72). 
 
The research done thus far does not indicate that milk production per cow will be 
changed. Treatment effectiveness is the same for older cows. The cost of discarded milk 
in the United States of America is reduced from $9.22 per cow to $1.40 per cow when 
milk is withheld for only 1 day during treatment (72). The cost of drugs is not anticipated 
to change. All current marketing investigations indicate that price competitiveness with 
antibiotics will be necessary for successful adoption (72). The result of bacteriocin 
administration should be similar to that of treatment with antibiotics. Labor requirements 
are decreased slightly, to the extent that first time infections can be treated effectively 
during lactation and eliminated. A monetary value cannot be assessed yet. Cow 
replacement costs are not anticipated to change (72). 
 
Milk will not be adulterated because bacteriocins are compounds that enjoy GRAS status. 
There is therefore no need for a withholding period of the milk after treatment. Testing 
will be unnecessary. Enhanced fat production will be modest and noticeable only to the 
degree that first time infections are eliminated. Losses in cheese manufacturing should 
not occur if no antibiotics are used. Bacteriocins are organism-specific and should not 
inhibit starter cultures or cause casein or fat decomposition (72). 
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Peptide AS-48, produced by Enterococcus faecalis FAIRE 92, inhibited the growth 
of a pathogenic strain of Staphylococcus aureus isolated from mastitic milk. In vivo 
activity tests were done by infusing infection-free udder quarters with 3.3 x 103 
cfu/ml of a pathogenic strain of S. aureus, in the presence or absence of peptide AS-
48. Relative to the control quarters, reduction in somatic cell (SCC) and S. aureus 
counts in quarters pre-treated with peptide AS-48 amounted to 50% and 90%, 
respectively. In a second experiment, already infected udder quarters of lactating 
cows were treated with peptide AS-48 or left untreated. The activity tests were done 
with purified peptide AS-48, obtained by using a combination of Triton X-114 phase 
partitioning and cation exchange chromatography. Reduction in SCC and S. aureus 
counts in quarters treated with peptide AS-48 amounted to 80% and 94%, 
respectively, when compared to the control quarters. Encapsulated peptide AS-48 
was used in the in situ activity tests. The efficiency of encapsulation varied between 
12 and 25%. Conjugation of the plasmid encoding peptide AS-48 (p92) to E. faecalis 
FA2/Ent, already producing enterocins 1071A and 1071B, was also performed. The 
presence of plasmid p92 was confirmed with Southern blot hybridization 
experiments. Other mastitic isolates that were also inhibited were Streptococcus 
agalactiae and Streptococcus dysgalactiae, but not Escherichia coli. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 96
S. aureus is one of the most common etiological agents of bovine mastitis in lactating 
dairy cows and contributes to significant economic losses in the dairy industry (9, 20). 
Despite mastitis management programs to reduce the incidence of intramammary udder 
infections (IMI), S. aureus remains a major problem (20). In the Western Cape of South 
Africa, S. aureus is responsible for 40% of all mastitis cases reported. After entering the 
mammary gland through the teat canal, the bacteria multiply rapidly, leading to 
inflammation and tissue damage (9). Apart from the infection, S. aureus secretes various 
toxins and enzymes, which may lead to food poisoning when the milk is consumed (3). 
Staphylococci found in infected tissues are mainly located extracellularly (14). However, 
virulent staphylococci such as S. aureus can survive within leukocytes following 
phagocytosis. Studies have shown that cells of S. aureus can penetrate into developing 
phagocytic cells (2, 9, 14). The adhesion of S. aureus to the epithelium cells is considered 
the first and most crucial event of infection (24). Antibiotics are routinely administered at 
drying-off to assist in the elimination of subclinical cases and prevent new IMIs from 
becoming established (20). However, animals infected with S. aureus respond poorly to 
antibiotic treatment (25), probably due to the intracellular location of the bacterial cells in 
the alveoli and/or macrophages (2, 9). Although many of the antibiotics that are used 
penetrate neutrophils, S. aureus may survive (5) and cause chronic intraphagocytic 
infections (14). 
Improved efficacy may be achieved by incorporating antimicrobial compounds in 
liposomes, which in turn deliver the compounds to phagocytic cells and accumulate 
intracelluarly (5, 14). Upon phagocytosis of the liposomes, the antimicrobial compound is 
released into the phagolysosome (5). 
The emergence of antibiotic resistance in bacteria has lead to a considerable debate in the 
use of antibiotics for prophylactic treatment. The World Health Organization issued 
recommendations on global programs to try and reduce the use of antibiotics. Such a 
limitation requires the consideration of alternative treatments (20). 
Immunization against S. aureus does not prevent IMI (13), as evident from the lack of 
high concentrations of antibody and phagocytic cells in the milk. Furthermore, 
inadequate knowledge of the pathogenesis of staphylococcal mastitis and the immune 
mechanisms protecting the mammary gland from infection has limited the scope for 
novel approaches to vaccination (24). 
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Attractive alternatives may include the use of lactic acid bacteria, and specifically 
bacteriocins, to achieve a low cost-effective method of preventing and treating S. aureus 
infections. In a previous study (15) Nisin was used in combination with lysostaphin to 
treat mastitis caused by S. aureus. Only 66% of the infections could be cured. Lacticin 
3147, incorporated into a teat seal (1280 AU/ml), killed 99.9% of S. aureus (16). 
We performed in vitro and in situ tests to determine the inhibitory activity of peptide AS-
48 (classified as a bacteriocin) against a pathogenic strain of S. aureus isolated from 
mastitic milk. In situ activity tests were done with peptide AS-48 encapsulated in 
liposomes. Conjugation of the plasmid p92 encoding peptide AS-48 to E. faecalis 
FA2/Ent, which produces enterocins 1071A and 1071B, was also performed. The 
transformant, E. faecalis FA2/Ent/AS-48 displayed a broader spectrum of antimicrobial 
activity and may even be more effective as an anti-mastitic treatment. 
 
 
MATERIALS AND METHODS 
 
Bacterial strains and growth conditions. E.  faecalis FAIRE 92, the producer of peptide 
AS-48, was obtained from prof. W. H. Holzapfel, BFE, Karslruhe, Germany. E. faecalis 
FA2/Ent was constructed in a previous study (Balla et al., 2000) and harbours plasmid 
pEF1071, which contains the genes encoding enterocins 1071A and 1071B. All 
enterococci were cultured in brain heart infusion (BHI) broth (Biolab Diagnostics, 
Midrand, South Africa). The indicator strains used in this study (Table 1) were from the 
Laboratorium voor Microbiologie, University of Ghent (LMG), Ghent, Belgium and our 
own culture collection. Strains of S. aureus, S. agalactiae, S. dysgalactiae and E. coli 
were isolated from mastitic milk and obtained from the Diagnostic Veterinary 
Laboratory, Stellenbosch, South Africa. All lactic acid bacteria were grown in MRS broth 
(Biolab). Other indicator bacteria were cultured in BHI broth (Biolab). 
Production and inhibitory activity of peptide AS-48. An overnight culture (10 ml) of 
E. faecalis FAIRE 92 was inoculated into 1 liter of BHI-G broth (BHI broth 
supplemented with 1% (wt/vol) glucose and 0.15 M NaH2PO4⋅H2O) and incubated at 
37oC without aeration until stationary growth. On an hourly basis 1 ml was sampled, 
serially diluted and plated onto BHI Agar (Biolab) and the number of viable cells 
(cfu/ml) determined. At the same time 1 ml of the cell-free supernatant was sampled, 
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adjusted to a pH between 6.0 and 7.0 with 1 N sterile NaOH, concentrated ten-fold and 
tested for activity against S. aureus by using the spot-on-lawn method (23). One arbitrary 
unit (AU) of peptide AS-48 is defined as the reciprocal of the highest dilution of the 
bacteriocin that produced an inhibition zone of at least 2 mm in diameter. From the 
antimicrobial activity, expressed as AU/ml, and the cell count (log10 cfu/ml) the specific 
activity ([AU/ml]/ [log10 cfu/ml]) was determined.   
Isolation, purification and concentration. Peptide AS-48 was isolated and purified 
according to the method described by Métivier et al. (12). One liter of BHI-G broth was 
inoculated with 10 ml of an actively growing culture of E. faecalis FAIRE 92 and 
incubated for 7 h at 37oC. Cells were harvested by centrifugation (9000 x g, 4oC) and 
Triton TX-114 added to the supernatant to obtain a final concentration of 2% (wt/vol). 
The sample was adjusted to pH 5.5 with concentrated HCl, heated to 25-30oC, and 
incubated at this temperature for 1-2 h, after which the upper-phase was removed and 
replaced with the same volume of cold Millipore water (Ω18.2) containing Triton TX-
114 (0.2%, wt/vol). The Triton TX-114 was dissolved by careful stirring. The mixture 
was heated to 25-30oC and left to separate into phases. The lower detergent-rich phase 
was recovered, diluted five-fold with cold Millipore water, and loaded onto a 15 ml SP-
Sepharose Fast flow column (Amersham Pharmacia Biotech, Uppsala, Sweden). The 
column was washed with cold Millipore water until a constant baseline absorbance at 280 
nm was reached. The loading and washing was done at 8oC to avoid phase partitioning. 
The bacteriocin was eluted with an ammonium acetate step-gradient of 0.1- 1.6 mol/liter-1 
(pH 6.0). Fractions of 4 ml were collected, concentrated by freeze-drying, dissolved in 
100 μl Millipore water and tested for activity against S. aureus, as described before. The 
active samples were pooled and stored at -80oC. Purified peptide AS-48 was also tested 
against S. agalactiae, S. dysgalactiae and E. coli.  
Sensitivity to proteolytic enzymes. Purified peptide AS-48 (3200 AU/ml) was used in 
these tests. Resistance of peptide AS-48 to proteolytic enzymes was determined by 
incubation in the presence of proteinase K (20 U/mg of peptide AS-48), pronase (7 U/mg 
of peptide AS-48), pepsin (2500 U/mg of peptide AS-48), papain (30 U/mg of peptide 
AS-48), α-chymotrypsin (90 U/mg of peptide AS-48) and trypsin (110 U/mg of peptide 
AS-48) at 37oC for 1 h. All enzymes were from Boehringer-Mannheim (Howard Place, 
South Africa) and tested at their optimum activity pH. After incubation, the enzymes 
were heat-inactivated for 3 min at 100oC and peptide AS-48 tested for antimicrobial 
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activity against S. aureus. The activity of the treated samples was compared to that of a 
control sample, i.e. peptide AS-48 that has not been treated with proteolytic enzymes. 
Molecular mass determination. A sample collected after separation in SP-Sepharose 
was subjected to tricine-SDS-polyacrylamide gel electrophoresis (SDS-PAGE), 
according to the method described by Schägger and Von Jagow (19).  A protein marker 
with sizes ranging from 2.35 to 46 kDa (Rainbow Marker; Amersham Pharmacia 
Biotech, Uppsala, Sweden) was used. One half of the gel was stained with Coomassie 
Brilliant Blue R250. The position of the active peptide AS-48 in the gel was determined 
by overlaying the other half of the gel, prewashed as described by Van Belkum et al. 
(22), with cells of an overnight grown culture of S. aureus, embedded in BHI agar 
(0.75% agar, wt/vol). In another experiment approximately 100 pmol of purified sample 
containing the bacteriocin was diluted in 10 μl of 10:90 acetonitrile-water containing 
0.01% formic acid and injected via the Rheodyne injection port of a Quattro triple 
quadropole mass spectrometer (Micromass, Manchester, United Kingdom). The carrier 
solvent was 10:90 acetonitrile-water at a flow rate of 20 μl/min, delivered by a 
Pharmacia-LKB 2249 high-pressure liquid chromatography pump. The capillary voltage 
and the cone voltage were set at 3.5 kV and 60 V, respectively. Data were collected by 
scanning from 400 to 1500 m/z at 2 s/scan. The multiple charged spectra were 
deconvoluted to obtain the accurate mass of the peptides. Calibration was done by using 
horse heart myoglobin (Sigma, St. Louis, Mo). 
Preparation of liposomes and determination of encapsulation efficiency. The method 
of Degnan and Luchansky (4) was used. Multilamellar vesicles were prepared using 
phosphatidyl choline from Sigma Chemical Co., St. Louis, MO (100 mg/ml chloroform). 
Four ml methanol/chloroform (1:1) and 2 ml phosphatidylcholine/chloroform mixture 
was placed into a 500 ml round-bottom flask and the solvent removed through rotary 
evaporation (37oC, 60 rpm, 30 min, under vacuum). After evaporation, a thin, opaque 
lipid film was formed on the inner surface of the flask. An aliquot of peptide AS-48 (5 
ml, 6400 AU/ml) and about 8 glass beads (4 mm in diameter; Fisher Scientific, 
Pittsburgh, PA) were added to the contents of the flask and rotated for a further 1 h at 
atmospheric pressure. The suspension (5 ml) was then incubated at 37oC for 2 h to 
complete swelling of the liposomes. The peptide AS-48/liposome preparation was then 
transferred to a sterile 15 ml polypropylene test tube and stored at 4oC for 7 days. The 
encapsulation efficiency (E%) was determined by adding 45 μl of the peptide AS-
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48/liposome suspension to each of two microcentrifuge tubes. Five μl proteinase K (10 
mg/ml) was added to one of the tubes to inactivate free, i.e. non-encapsulated, peptide 
AS-48. Sterile distilled water was added to a second tube. The samples were incubated at 
37oC for 1-2 h and then heated (100oC, 3 min) to inactivate proteinase K and at the same 
time release encapsulated peptide AS-48 from the intact liposomes. The antimicrobial 
activity of released peptide AS-48 was determined by using the spot-on-lawn method, as 
described before. The E% was calculated as follows: E% = activity (AU/ml) of peptide 
AS-48 in the liposome mixture treated with proteinase K divided by the activity (AU/ml) 
of peptide AS-48 in the liposome mixture to which sterile distilled water was added 
(x100).  
Antimicrobial activity assays. One ml of encapsulated peptide AS-48 (3200 AU/ml) 
was added to a 100 ml culture of S. aureus at the beginning of the lag and mid-
exponential growth phases, respectively. Sterile demineralized water (1 ml) was added to 
the control flask. Changes in the turbidity of the cultures were recorded at 600 nm, and 
the number of viable cells (cfu/ml) was determined by plating the samples onto BHI Agar 
(Biolab). 
In situ activity tests: 
Prevention experiment: Ten teats of five cows with somatic cell counts (SCC) < 500 000 
cells/ml were selected. This threshold value gives a good indication of mastitis and milk 
with a SCC higher than it usually contains pathogenic organisms. Milk from these teats 
contained no viable cells of S. aureus, as determined by plating onto Baird-Parker Agar. 
Five teats were individually infused with 1 ml encapsulated peptide AS-48 (6400 
AU/ml), followed by 2 ml of S. aureus (3.3 x 103 cells/ml). The other five teats that acted 
as controls were treated the same as above, except that 1 ml saline solution (0.75% NaCl) 
was used instead of peptide AS-48. Infusion was done immediately after milking, thus on 
day 1 of milk collection. The AS-48 peptide and S. aureus cells were massaged upwards 
into the teats. Milk samples were collected daily (up to day 7) from which viable cells of 
S. aureus and SCC counts were determined. It is conceded that the number of replication 
was relatively low. It was, however, dependant on the number of available cows in a 
specific stage of lactation. Since the microbial challenge with S. aureus was expected to 
result in marked changes in SCC and S. aureus counts, the number of replicates was 
regarded as sufficient for the purposes of this study. Moreover, since only a marked 
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response would be of value for therapeutic purposes, it would be argued that a very high 
number of replicates is not advisable for an experiment of this nature.  
Statistical methods 
The SCC and S. aureus counts were variable, ranging from 1.7 x 104 to 9.6 x 106 cells/ml 
and from to low to be detected with the methods used to 1.92 x 105 cfu/ml, respectively. 
The counts were expressed as log10 values. Where no S. aureus was detected 100 was 
added to each count prior to analysis. The analyses were also complicated by the fact that 
ten different quarters of five individual cows were sampled as experimental units. The 
data could thus not be described as uncorrelated, as assumed for analysis of variance. 
This complication was accounted for by the estimation of the intraclass correlation 
depicting all possible correlations between repeated samples obtained from the cows (8). 
Covariation arising from the repeated samples from specific cows was not only accounted 
for by this procedure, but it was also possible to estimate the repeatability of SCC and S. 
aureus counts (21). Repeatability (t) was estimated as: 
t = σb2/ σb2 + σe2 
= σb2 the intraclass correlation between cows 
= σe2 the residual variation. 
 
Apart from the random effect of cows in the models used to analyze the data, fixed 
effects of treatment and days post treatment were included. The interaction between 
treatment and days post treatment was also estimated. 
Treatment experiment: Six teats of three cows with a SCC > 500 000 cells/ml were 
selected. Milk collected from these teats tested positive for S. aureus. This field strain of 
S. aureus was also tested as sensitive towards peptide AS-48. Three of these teats were 
infused with 1 ml encapsulated peptide AS-48 (6400 AU/ml). The other three teats acted 
as controls and were infused with 1 ml saline solution (0.75% NaCl). The infusion was 
done immediately after milking, thus on day 1 of milk collection. The samples were 
massaged into the teats. Milk samples were collected daily (up to day 7) from which 
viable S. aureus and SCC counts were determined. For this experiment the number of 
replication was also relatively low. Again it was dependant on the number of available 
cows in a specific stage of lactation and therefore the number of replicates was regarded 
as sufficient for the purposes of the study. Thus a high number of replicates is again not 
advisable for this type of experiment.    
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Statistical Methods 
The SCC and S. aureus counts were variable, ranging from 1.8 x 105 to 1 x 107 cells/ml 
and from to low to be detected with the methods used to 1.5 x 105 cfu/ml respectively. 
Data were analyzed as a 2 (treatments) x 7 (day) factorial design. As for the prevention 
experiment the analysis was complicated by the fact that the same quarter was sampled 
repeatedly. The same basic procedure was followed to account for repeated sampling. 
The difference was that individual quarters were confounded with treatments in this 
instance. The appropriate analysis was thus to nest individual quarters within treatments. 
Repeatability was estimated from between quarter variance components as described 
previously. 
Conjugative transfer experiments. Filter mating experiments were done as described 
by Reichelt et al. (15). An overnight culture of E. faecalis FAIRE 92 (500 μl) and E. 
faecalis FA2/Ent (500 μl) was added to 10 ml of MRS, mixed and filtered through a 0.45 
μm pore-size sterile membrane (HAWP, Millipore). The membrane was placed onto 
MRS agar and incubated overnight at 37oC. The cells were washed from the membrane 
and suspended in 2 ml MRS, serially diluted, and placed onto MRS agar plates containing 
25 μg fucidic acid, 25 μg rifampicin, 2133.3 AU/ml purified peptide AS-48 and 533.3 
AU/ml crude enterocin 1071A and 1071B. The antibiotics used were inhibitory towards 
E. faecalis FAIRE 92 but not against E. faecalis FA2/Ent, while both bacteriocins were 
inhibitory towards opposite producing strains. Colonies were selected at random and 
screened for plasmid content by using standard techniques (Sambrook et al., 1989) A 
colony of conjugated cells of E. faecalis FA2/Ent that contained plasmid p92 (conjugant 
FA2/Ent/92) was cultured, and the cell-free supernatant was subjected to peptide AS-48 
purification and mass spectrometry analysis, as described above. 
Southern blot hybridization. Southern blot hybridizations were performed as described 
by Sambrook et al. (17). The plasmid DNA of E. faecalis FA2/Ent/92 was hybridized 
with a 200 bp probe made from a fragment containing part of the peptide AS-48 
structural gene, from plasmid pAM 401-61 (11). The same DNA was also hybridized 
with the 8 kb plasmid, pBEco2, which contains a 2 kb fragment of the enterocin 1071A 
and B structural gene, as well as part of the abc transporter gene (3). Detection was by 
DNA probes radioactively marked with 32P[dATP] (Amersham Pharmacia Biotech, 
Uppsala, Sweden). 
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RESULTS 
 
Production and inhibitory activity of peptide AS-48. The highest activity levels of 
peptide AS-48 (148.15 AU/log10cfu) was recorded during late exponential growth, after 7 
h of fermentation (Fig. 1). Slight antimicrobial activity was recorded against S. aureus in 
a ten-fold concentrated, cell-free supernatant. Increased activity was only recorded when 
peptide AS-48 was isolated and purified. The titer of purified peptide AS-48 varied 
between 3200 and 12800 AU/ml. This corresponded to a two to eight-fold increase in 
specific antimicrobial activity after purification on SP-Sepharose. S. agalactiae and S. 
dysgalactiae were also inhibited, but not E. coli. 
Sensitivity to proteolytic enzymes. Peptide AS-48 was sensitive towards proteinase K, 
pronase, pepsin, papain, α-chymotrypsin and trypsin. 
Molecular mass determination. Mass spectrometry analysis indicated that the active 
samples, collected from the SP-Sepharose column and pooled together, contained a single 
peptide with a molecular mass of 7.150 kDa (Fig. 2). Separation on tricine-SDS-PAGE 
yielded only one active peptide band in the range of 6.4 kDa (Fig. 3). 
Liposome encapsulation. Encapsulation efficiencies varied between 10 and 25%. For 
the prevention experiment the titer of peptide AS-48 was 400 AU/ml after proteinase K 
treatment, compared to 3200 AU/ml for the control sample. This resulted in an 
encapsulation efficiency (E%) of 12.5%. In the case of the treatment experiment the titer 
of peptide AS-48 was 1600 AU/ml after proteinase K treatment, compared to 6400 
AU/ml of the control sample. This resulted in an E% of 25%. 
Antimicrobial activity. Addition of peptide AS-48 to S. aureus during the lag phase 
completely inhibited cell growth (Fig. 4). However, when peptide AS-48 was added 
during mid-exponential growth a slight decrease in viable cells for a very short period (30 
min) was recorded. Thereafter cell growth continued as before. During this period the 
specific antimicrobial activity increased from 307.69 AU/log10 cfu  (150 min.) to 354,37 
AU/log10 cfu (180 min.). After this the specific antimicrobial activity again decreased to 
stabilize at values of 277,3 AU/log10 cfu in the stationary phase.    
In situ activity tests: 
Prevention experiment. The variation accounted for by the repeated sampling of different 
cows was significant in the analysis involving SCC (P < 0.001) and S. aureus counts (P < 
0.05). Repeatability estimates (±SE) derived from these analyses were 0.26 ± 0.19 and 
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0.13 ± 0.13, respectively. Although these estimates could not be proven as significant (P 
< 0.05) from zero, the variation between cows controlled significant (P < 0.05) portions 
of the overall variation in both analyses. It was thus decided to retain this effect in the 
models used. 
The interaction between treatment and days post treatment was not significant (P = 0.79) 
as far as SCC were concerned. This interaction is presented in Fig. 5a. A sharp increase 
(P < 0.05) in SCC was recorded on day 2. Afterwards, SCC stabilized at the same 
approximate level. In quarters treated with peptide AS-48 the SCC were generally lower 
than in the control quarters, with a significant (P < 0.05) difference on day 6. When the 
overall mean values for treated and untreated quarters were compared, there was a 
significant (P < 0.01) difference in favor of the treated quarters (log10 transformed means 
5.710 ± 0.143 vs. 6.006 ± 0.143). When these mean values were transformed back to the 
normal scale they corresponded to a SCC of 512 625 for treated quarters and 1 013 911 
for control quarters. Expressed relative to the control treatment, the reduction in SCC in 
the treated quarters amounted to approximately 50%.  
In control quarters where no peptide AS-48 was included, S. aureus numbers increased (P 
< 0.05) linearly to reach a maximum of 3.4 ± 0.4 log10 cfu/ml on day 4. S. aureus counts 
decreased after day 4 and subsequently stabilized until day 7. The increase in S. aureus 
cell numbers in treated quarters was slower. Mean values for treated quarters were lower 
than for control quarters on day 4, 6 and 7 (Fig. 5b). In view of the fact that no significant 
(P < 0.05) interaction was found between treatment and days post treatment, it is 
appropriate to give overall mean values for treated and control quarters. These were (on 
the log10 scale) 2.785 ± 0.181 for control quarters and 2.181 ± 0.181 for treated quarters. 
Transformed back to the normal scale (with 100 subtracted) these means values 
correspond to respective S. aureus counts of 509 and 51, i.e. a near to 90% reduction in 
treated quarters.  
Treatment experiment. The between quarter variance was significant (P < 0.01) in 
analyses on SCC and S. aureus counts. The respective repeatability estimates derived 
from the variance components were 0.40 ± 0.25 and 0.41 ± 0.25. 
For SCC the interaction between treatment and days post treatment did not reach 
significance in this case (P = 0.06). Overall, SCC was reduced (P < 0.05) in treated 
quarters relative to control quarters (Fig. 6a). Overall mean values (±SE) for SCC were 
6.70 ± 0.12 for control quarters, compared to 6.01 ± 0.12 for treated quarters. 
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Corresponding antilogs were 5.03 x 106 and 1.03 x 106. Expressed relative to the control 
treatment, the reduction in treated quarters amounted to nearly 80%.  
In the case of S. aureus counts treatment interacted (P < 0.01) with the days of post 
treatment in this instance. In the case of untreated quarters, S. aureus counts basically 
remained on the same level throughout the monitoring period (Fig. 6b). In treated 
quarters there were a significant (P < 0.01) decline in S. aureus counts, to reach levels not 
significantly different (P < 0.05) from two, which corresponds to zero for 
backtransformed values. This decline was observed from day 4. Differences between 
mean values for treated and control quarters were significant (P < 0.05) from day 2 
onwards. Overall means (±SE) were 4.1 ± 0.3 for control quarters, compared to 2.91 ± 
0.26 for treated quarters. Transformed back to the normal scale (with 100 subtracted) 
these means correspond to respective S. aureus counts of 12 530 and 715, i.e. a reduction 
of up to 94% in treated quarters.  
Conjugative transfer experiments. The E. faecalis FA2/Ent transconjugants contained a 
plasmid of approx. 21 kb and produced peptide AS-48. Purification of peptide AS-48 by 
a combination of Triton X-114 phase partitioning and SP-Sepharose chromatography, 
followed by mass spectrometry, indicated the presence of a peptide with a molecular 
mass of 7.150 kDa (data not shown). The spectrum of antimicrobial activity for the 
peptides isolated from the transconjugant (E. faecalis FA2/Ent/92) is broader than that 
recorded for E. faecalis BFE 1071 (Table 1). 
Southern blot hybridization. Conjugation of plasmid p92 from E. faecalis FAIRE 92 to 
E. faecalis FA2/Ent did take place without the loss of pEF1071 (Fig. 7). 
 
 
DISCUSSION 
 
We have described the isolation and purification of the cyclic peptide AS-48 from E. 
faecalis FAIRE 92. The in situ antimicrobial activity of peptide AS-48 was evaluated as a 
means of reducing the number of viable cells of S. aureus in deliberately challenged as 
well as already infected quarters of lactating cows. In contrast to previous reports 
suggesting the broad inhibitory spectrum of peptide AS-48, which included the inhibition 
of E. coli, the spectrum of antimicrobial activity was narrower. Gram-negative organisms 
need higher concentrations because of the different concentrations of the active form of 
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peptide AS-48 and because of the presence of an outer membrane (6, 7, 10). However, 
the other major causative organisms of mastitis in the Western Cape, which include S. 
aureus, S. agalactiae and S. dysgalactiae, were inhibited. 
The molecular mass of the peptide isolated was 7.150 kDa and confirmed that E. faecalis 
strain FAIRE 92 produced peptide AS-48. This was further supported by the fact that 
only one active band, corresponding to the size of peptide AS-48, was detected on the 
tricine-SDS-PAGE gel (Fig. 3). Martínez-Bueno et al. (11) was unable to determine the 
protein sequence of peptide AS-48 by Edman degradation. In this study we ascribe this 
phenomenon to the cyclic nature of peptide AS-48. 
The E% compared good to the efficiencies previously achieved by the specific method 
used (4). On the other hand non-encapsulated peptide AS-48 holds the benefit of 
eliminating extracellularly located S. aureus, which is where the organism is mainly 
situated in infected tissue (14). 
Peptide AS-48 exerts its biological action by incorporating the peptide into the 
cytoplasmic membrane, forming pores that leak potassium and inorganic phosphate (6, 7, 
18). The fact that only a small decrease in the cell count was observed when encapsulated 
peptide AS-48 was added at a cell count of approximately 2.51 x 1010 may indicate that 
less AS-48 peptides were available per sensitive cell. The result was that the bacteriocin 
was present at sublethal concentrations for S. aureus (20). 
According to the results gained from the in situ tests it seems that peptide AS-48 had a 
better effect in the treatment experiment in comparison to the prevention experiment, 
when treated quarters were compared to untreated quarters. It must however be 
remembered that the mean SCC and S. aureus counts were lower for the prevention 
experiment in comparison to the treatment trial. Although S. aureus was not eliminated 
totally in either of the two experiments, the reduction of S. aureus counts in the treatment 
experiment was better than in the prevention experiment. The mean SCC count in the 
prevention experiment (512 625) is much closer to the upper limit of 500 000 for healthy 
cows. In the treatment experiment the mean SCC was 1.03 x 106. The results can partly 
be explained through the fact that initial SCC and S. aureus counts in the treatment 
experiment were much higher than recorded in the prevention experiment. 
The purpose of conjugating plasmid p92 from E. faecalis strain FAIRE 92 to E. faecalis 
strain FA2/Ent, already containing plasmid pEF1071, was to develop a strain with a 
broader antimicrobial spectrum and antimicrobial activity than E. faecalis FA2/Ent. This 
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strain would then be able to produce enterocins 1071A and 1071B, as well as peptide AS-
48. Initially, it was feared the plasmids might have the same origin of replication. This 
might have lead to the random selection of only one of the plasmids being replicated, 
since the amplification of only one of the plasmids would lead to the elimination of the 
other plasmid. However, southern blot hybridizations confirmed the presence of both 
plasmids in the recipient strain (Fig. 7). 
This study thus indicates the potential use of peptide AS-48 in the prevention and 
treatment of S. aureus mastitis. The only problem encountered was the low specific 
antimicrobial activity (296,30 to 1185,18 AU/log10 cfu). Further studies should thus be 
aimed at this problem before the potential use of peptide AS-48 in mastitis control can be 
exploited.  
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FIG. 1. Production of peptide AS-48 during the growth of E. faecalis FAIRE 92. g 
Growth of E. faecalis FAIRE 92. S Specific antimicrobial activity of peptide AS-48 
during the growth of E. faecalis FAIRE 92. 
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FIG. 2. Molecular mass of peptide AS-48 calculated from the electrospray ionization-
mass spectrometry multiple charged spectra. 
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FIG. 3. Seperation of peptide AS-48 by tricine-SDS-PAGE. Lane 1 , Rainbow protein 
size markers; lane 2, peptide AS-48 stained with Coomassie brilliant blue R250; lane3, 
peptide AS-48 overlaid with cells of mastitic S. aureus embedded in BHI Agar (0.75% 
agar, wt/vol). The active peptide band is indicated by an arrow.  
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FIG. 4. Effect of peptide AS-48 on the growth of S. aureus. Counts were made in the 
absence of peptide AS-48 () and in the presence of peptide AS-48 added at the 
beginning of the lag phase (S) and during mid-exponential growth (). Turbidity was 
determined for cells growing in the absence of peptide AS-48 () and in the presence of 
peptide AS-48 at the beginning of the lag phase (U) and during mid-exponential growth 
(). 
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FIG. 5(a). The influence of treatment with peptide AS-48 on SCC relative to an untreated 
control. Each mean is based on five replicates. The experimental design involved five 
cows with on teat randomly assigned to the treated and control groups respectively. 
Vertical bars denote standard errors. 
 
 
FIG. 5(b). The influence of treatment with peptide AS-48 on cell numbers of S. aureus 
relative to an untreated control. Each mean is based on five replicates. The experimental 
design involved five cows with on teat randomly assigned to the treated and control 
groups respectively.  Vertical bars denote standard errors. 
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FIG. 6(a). The influence of treatment of infected quarters with peptide AS-48 on SCC 
relative to untreated control quarters. Each mean is based on three replicates. The 
experimental design involved three cows with on teat randomly assigned to the treated 
and control groups respectively. Vertical bars denote standard errors. 
 
 
FIG. 6(b). The influence of treatment of infected quarters with peptide AS-48 on S. 
aureus counts relative to untreated control quarters. Each mean is based on three 
replicates. The experimental design involved three cows with on teat randomly assigned 
to the treated and control groups respectively. Vertical bars denote standard errors. 
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FIG. 7. Plasmid profiles of E. faecalis FA2/Ent/92 after conjugation of plasmid p92. (a) 
Comparison of the plasmid profiles of E. faecalis FAIRE 92 and the transconjugant. Lane 
1, 1 kb marker; lane 2, plasmid p92 (uncut); lane 3, plasmid p92 (digested with Sal I); 
lane 4, transconjugant (digested with Sal I); lane 5, transconjugant (uncut). (b) The same 
gel after Southern blotting onto a MagnaGraph nylon transfer membrane (MSI, 
Westboro, Mass.) and hybridized with a radioactively labeled 32P[dATP] 200 bp EcoRI 
and NdeI isolated fragment of plasmid pAM 401-61 containing part of the peptide AS-48 
structural gene. (c) Comparison of the plasmid profiles of E. faecalis FA2/Ent and the 
transconjugant. Lane 1, 1 kb marker; lane 2, plasmid p92 (digested with Eco RV); lane 3, 
FA2/Ent (uncut); lane 4, FA2/Ent (digested with Eco RV); lane 5, transconjugant 
(digested with Eco RV); lane 6, transconjugant (uncut). (d) The same gel after Southern 
blotting onto a MagnaGraph nylon transfer membrane (MSI, Westboro, Mass.) and 
hybridized with a radioactively labeled 32P[dATP] plasmid pBEco2 containing a 
fragment of the enterocins 1071A and 1071B structural gene. 
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TABLE 1. Spectrum of antimicrobial activity of ammonium sulfate precipitated 
supernatant of Enterococcus faecalis FA2/Ent/92 (transconjugant). 
Organisma Strain(s)b Sensitivityc 
Bacillus cereus 
Enterococcus faecalis 
Lactobacillus acidophilus 
Lactobacillus casei 
Lactobacillus curvatus 
Lactobacillus fermentum 
Lactobacillus plantarum 
Lactobacillus reuteri 
Lactobacillus sakei 
Leuconostoc cremoris 
Leuconostoc pentosaceus 
Staphylococcus aureus 
Staphylococcus carnosus 
LMG 13569 
BFE 1071d 
LMG 13550 
LMG 13552 
LMG 13553 
LMG 13554 
LMG 13556 
LMG 13557 
LMG 13558 
LMG 13562, 13563 
LMG 13560, 13561 
MKB 38 
LMG 13567 
++ 
+++ 
++ 
++ 
++++ 
++ 
+ 
+ 
++ 
++ 
+++ 
+ 
++ 
a Organisms resistant to the antimicrobial effect of enterocins 1071A and 1071B. 
b Abbreviations: LMG, Laboratorium voor Microbiologie, University of Ghent, Ghent, 
Belgium; MKB, Department of Microbiology, University of Stellenbosch, Stellenbosch, 
South Africa. 
c +, sensitive to peptide AS-48 (+, ++, +++, ++++ reflect the degree of sensitivity). 
d Enterocins 1071A and 1071B producer strain. 
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GENERAL DISCUSSION AND CONCLUSIONS 
 
The dairy industry provides a valuable feed source to any nation. In South Africa, milk is 
produced under conditions which are regarded as sub-optimal for effective dairy farming. 
A low milk yield is mainly due to poor feeding, management, hygiene, and general health 
practices. Determined efforts should be made to rectify this and also to improve udder 
health by controlling and preventing mastitis, which is the most expensive disease 
confronting dairy farmers (3). 
 
Mastitis causes a decrease in the milk yield of dairy cows, whilst it also changes the milk 
composition. Expenditures and adverse effects include an increase in the replacement 
heifer costs because of a shorter productive life, drug and veterinary costs, extra labour 
and loss of genetic material from the herd. Treatment of mastitis in South Africa 
amounted to R380 million in 1994 and is estimated to increase to R480 million in 2003. 
In South Africa only 40% of all cows have a healthy udder. The other 60% have some 
degree of mastitis (3). 
 
Bacterial infection is the most common cause of mastitis and most of the cases can be 
attributed to staphylococci, streptococci and coliform bacteria. In the Western Cape of 
South Africa, Staphylococcus aureus is responsible for 40% of all mastitis cases reported. 
The organism is relatively resistant to disinfectants and many of the commonly used 
antibiotics. Apart from the infection, S. aureus secretes various toxins and enzymes and 
consumption of contaminated milk may result in food poisoning (2). 
 
Prevention of staphylococcal infections by immunisation has been abandoned as it was 
found not to be a practical method. The reasons for this are the existence of so many 
different staphylococcal strains and inadequate knowledge of the pathogenesis of 
staphylococcal mastitis and the immune mechanisms protecting the mammary gland from 
infection (1, 5). 
 
Attractive alternatives may include the use of lactic acid bacteria, and specifically 
bacteriocins, to achieve a low cost-effective method of preventing and treating S. aureus 
infections. In a previous study nisin, in combination with lysostaphin, could only cure 
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66% of infections caused by S. aureus (15). Lacticin 3147, incorporated into a teat seal, 
killed > 99.9% of S. aureus cells when used at a concentration of 1280 AU/ml (4). 
 
In this study, we determined, in vitro and in vivo, the inhibitory activity of the cyclic 
peptide AS-48, classified as a bacteriocin, against a strain of S. aureus isolated from 
mastitic milk. Peptide AS-48, produced by Enterococcus faecalis strain FAIRE 92, is 
produced maximally during late exponential growth, i.e. after 7 h of fermentation. At this 
time the specific antimicrobial activity corresponds to 148.15 AU/ml in a ten-fold 
concentrated, cell-free supernatant. Purification of this crude extract of peptide AS-48 
yielded a two to eight-fold increase in specific antimicrobial activity (from 148.15 to 
296.29-1185.18 AU/ml). Peptide AS-48 was also active against Streptococcus agalatiae 
and Streptococcus dysgalactiae but not Escherichia coli. The proteinaceous nature of 
peptide AS-48 was confirmed by its sensitivity to proteolytic enzymes. The molecular 
mass of peptide AS-48 was determined at 7 150 Da and is in agreement with the size of 
the peptide isolated from other strains of E. faecalis. Peptide AS-48 added to lag-phase 
cells of S. aureus completely inhibited cell growth. However, when peptide AS-48 was 
added during mid-exponential growth a slight decrease in viable cells for a very short 
period (30 min) was recorded. Thereafter cell growth continued as before. 
 
An in vivo study was conducted by administering peptide AS-48 (6400 AU/ml) to 
different quarters of the udders of cows, deliberately or already infected with S. aureus. 
In situ activity tests were done with peptide AS-48 encapsulated in liposomes. This was 
done to protect peptide AS-48 against proteolytic breakdown in the udder. Encapsulation 
would also lead to a slower release of the peptide in the udder and a more sufficient 
localization at the site of infection. Encapsulation efficiencies (E%) varied between 12 
and 25%, which are good in comparison to the encapsulation of other peptides done 
according to the method used. 
 
In the prevention experiment the reduction in SCC and S. aureus cell counts in the treated 
quarters amounted to 50% and 90%, respectively. The reduction in SCC and S. aureus 
cell counts in the treatment experiment amounted to 80% and 94%, respectively. 
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Conjugation of plasmid p92, which harbours the genes encoding peptide AS-48, to E. 
faecalis FA2-2, which contains plasmid pEF1071 encoding enterocins 1071A and 1071B, 
was done to construct a strain with a broader antimicrobial spectrum and antimicrobial 
activity than E. faecalis FA2/Ent. In addition, this may well prevent resistances of the 
target strains from occurring.  Conjugation of plasmid p92 to strain FA2-2 was successful 
without the loss of plasmid pEF1071, although plasmid loss was not tested over many 
generations. The spectrum of antimicrobial activity recorded for the transconjugant E. 
faecalis FA2/Ent/92 was broader than that recorded for E. faecalis BFE 1071. Organisms 
inhibited after conjugation of plasmid p92 include Lactobacillus acidophilus, 
Lactobacillus casei, Lactobacillus curvatus, Lactobacillus fermentum, Lactobacillus 
plantarum, Lactobacillus reuteri, Lactobacillus sakei, Leuconostoc cremoris, 
Leuconostoc pentosaceus, Bacillus cereus, Staphylococcus carnosus, S. aureus and E. 
faecalis. Southern blot hybridisations confirmed the presence of both plasmids in the 
recipient strain.  
 
Results obtained in this study indicated that peptide AS-48 could be used in the 
prevention and treatment of S. aureus mastitis. Future research might be aimed at 
enhancing the specific antimicrobial activity of peptide AS-48 through fermentation 
studies. Future studies with the transconjugant strain may include using enterocins 1071A 
and 1071B as well as peptide AS-48, encapsulated in liposomes, in other in situ studies. 
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